index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
10201,Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain,"Abstract Objective: The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (=5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain. Methods: The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year. Results: Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than ?30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis. Conclusions: For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.",2012-01-09716,22954062,J Med Econ,Vivencio Barrios,2012,15Suppl1 /,45-54,Yes,22954062,"Vivencio Barrios; Jos? M Lobos; Adalberto Serrano; Max Brosa; Margarita Capel; Concha Alvarez Sanz; Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain, J Med Econ, ; 15Suppl1():1369-6998; 45-54",QALY,Spain,Not Stated,Not Stated,Rosuvastatin vs. Atorvastatin,Not Stated,Not Stated,Not Stated,Male,Full,20 Years,3.00,3.00,11000,Euro,2010,17278.68
10202,Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain,"Abstract Objective: The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (=5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain. Methods: The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year. Results: Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than ?30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis. Conclusions: For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.",2012-01-09716,22954062,J Med Econ,Vivencio Barrios,2012,15Suppl1 /,45-54,Yes,22954062,"Vivencio Barrios; Jos? M Lobos; Adalberto Serrano; Max Brosa; Margarita Capel; Concha Alvarez Sanz; Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain, J Med Econ, ; 15Suppl1():1369-6998; 45-54",QALY,Spain,Not Stated,Not Stated,Rosuvastatin vs. Atorvastatin,Not Stated,55 Years,55 Years,Female,Full,20 Years,3.00,3.00,39000,Euro,2010,61260.79
10203,Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain,"Abstract Objective: The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (=5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain. Methods: The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year. Results: Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than ?30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis. Conclusions: For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.",2012-01-09716,22954062,J Med Econ,Vivencio Barrios,2012,15Suppl1 /,45-54,Yes,22954062,"Vivencio Barrios; Jos? M Lobos; Adalberto Serrano; Max Brosa; Margarita Capel; Concha Alvarez Sanz; Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain, J Med Econ, ; 15Suppl1():1369-6998; 45-54",QALY,Spain,Not Stated,Not Stated,Rosuvastatin vs. Atorvastatin,Not Stated,55 Years,55 Years,Female,Full,20 Years,3.00,3.00,28000,Euro,2010,43982.1
10204,Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain,"Abstract Objective: The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (=5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain. Methods: The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year. Results: Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than ?30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis. Conclusions: For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.",2012-01-09716,22954062,J Med Econ,Vivencio Barrios,2012,15Suppl1 /,45-54,Yes,22954062,"Vivencio Barrios; Jos? M Lobos; Adalberto Serrano; Max Brosa; Margarita Capel; Concha Alvarez Sanz; Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain, J Med Econ, ; 15Suppl1():1369-6998; 45-54",QALY,Spain,Not Stated,Not Stated,Rosuvastatin vs. Atorvastatin,Not Stated,55 Years,55 Years,Male,Full,20 Years,3.00,3.00,10000,Euro,2010,15707.89
10205,Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain,"Abstract Objective: The objective of this study was to carry out a long-term cost-effectiveness analysis of rosuvastatin compared with generic atorvastatin in the treatment of patients at high cardiovascular (CV) risk (=5% Systematic COronary Risk Evaluation [SCORE]) and patients with prior cardiovascular disease (CVD) in Spain. Methods: The efficacy data from the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) study were used to simulate achievement of low-density lipoprotein cholesterol targets with different doses of rosuvastatin and generic atorvastatin for an initial period of 1 year. A Markov model was used to estimate the number of CV complications, quality-adjusted life years (QALYs), and healthcare costs (lipid-lowering treatment and CV events) for up to 20 years after initial treatment. The analysis was carried out from the perspective of the Spanish National Health System, with costs (in year 2010 euros) and effects being discounted at 3% per year. Results: Compared with generic atorvastatin, rosuvastatin was cost-effective (cost per QALY gained of less than ?30,000) for the primary prevention of CV events in high-risk patients in most sub-groups analyzed. In patients with prior CVD, rosuvastatin was cost-effective in all sub-groups of men and most sub-groups of women. Key limitations of this study were the need to extrapolate data from a single trial to long-term modeled outcomes and the absence of other treatment options in the analysis. Conclusions: For the treatment of dyslipidemic patients with high CV risk, rosuvastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.",2012-01-09716,22954062,J Med Econ,Vivencio Barrios,2012,15Suppl1 /,45-54,Yes,22954062,"Vivencio Barrios; Jos? M Lobos; Adalberto Serrano; Max Brosa; Margarita Capel; Concha Alvarez Sanz; Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain, J Med Econ, ; 15Suppl1():1369-6998; 45-54",QALY,Spain,Not Stated,Not Stated,Rosuvastatin vs. Atorvastatin,Not Stated,55 Years,55 Years,Male,Full,20 Years,3.00,3.00,13000,Euro,2010,20420.26
10206,Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore,"Asians who carry the HLA-B*1502 allele have an elevated risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with the antiepileptic drugs (AEDs) carbamazepine (CBZ) and phenytoin (PHT). With a focus on Singapore, this analysis identifies circumstances in which genotyping and targeted treatment with alternative AEDs that do not induce SJS/TEN is likely to be more cost-effective than 1) treatment with CBZ or PHT without genotyping or 2) providing a more expensive drug that does not induce SJS/TEN to all patients without genotyping.A decision tree model was developed in TreeAge. The model takes into account costs of epilepsy treatments and genotyping, reductions in quality of life and increased costs resulting from SJS/TEN complications, the prevalence of the risk allele, the positive predictive value (PPV) of genotyping, life expectancy, and other factors.Compared with no genotyping and providing CBZ to all, genotyping results in an incremental cost-effectiveness ratio of $37,030/quality-adjusted life year (QALY) for Chinese patients, $7,930/QALY for Malays, and $136,630/QALY for Indians in Singapore.Because of the different population allele frequencies of HLA-B*1502 among different ethnic groups, genotyping for HLA-B*1502 and providing alternate AEDs to those who test positive is cost-effective for Singaporean Chinese and Malays, but not for Singaporean Indians. Population frequency of HLA-B*1502, PPV, duration of treatment relative to life expectancy, and costs of alternative drugs are the key drivers influencing cost-effectiveness.",2012-01-09718,22955130,Neurology,Di Dong,2012,79 / 12,1259-67,No,22955130,"Di Dong; Cynthia Sung; Eric Andrew Finkelstein; Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore, Neurology, Sep/18/2012; 79(12):1526-632X; 1259-67",QALY,Singapore,Not Stated,Not Stated,Genotyping and providing valproate (VPA) for patients who test positive and carbamazepine (CBZ)/phenytoin (PTH) for patients who test negative vs. No genotyping and CBZ or PHT for all patients,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,29750,United States,2010,35310.32
10207,Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore,"Asians who carry the HLA-B*1502 allele have an elevated risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with the antiepileptic drugs (AEDs) carbamazepine (CBZ) and phenytoin (PHT). With a focus on Singapore, this analysis identifies circumstances in which genotyping and targeted treatment with alternative AEDs that do not induce SJS/TEN is likely to be more cost-effective than 1) treatment with CBZ or PHT without genotyping or 2) providing a more expensive drug that does not induce SJS/TEN to all patients without genotyping.A decision tree model was developed in TreeAge. The model takes into account costs of epilepsy treatments and genotyping, reductions in quality of life and increased costs resulting from SJS/TEN complications, the prevalence of the risk allele, the positive predictive value (PPV) of genotyping, life expectancy, and other factors.Compared with no genotyping and providing CBZ to all, genotyping results in an incremental cost-effectiveness ratio of $37,030/quality-adjusted life year (QALY) for Chinese patients, $7,930/QALY for Malays, and $136,630/QALY for Indians in Singapore.Because of the different population allele frequencies of HLA-B*1502 among different ethnic groups, genotyping for HLA-B*1502 and providing alternate AEDs to those who test positive is cost-effective for Singaporean Chinese and Malays, but not for Singaporean Indians. Population frequency of HLA-B*1502, PPV, duration of treatment relative to life expectancy, and costs of alternative drugs are the key drivers influencing cost-effectiveness.",2012-01-09718,22955130,Neurology,Di Dong,2012,79 / 12,1259-67,No,22955130,"Di Dong; Cynthia Sung; Eric Andrew Finkelstein; Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore, Neurology, Sep/18/2012; 79(12):1526-632X; 1259-67",QALY,Singapore,Not Stated,Not Stated,Genotyping and providing valproate (VPA) for patients who test positive and carbamazepine (CBZ)/phenytoin (PTH) for patients who test negative vs. No genotyping and CBZ or PHT for all patients,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,37030,United States,2010,43950.96
10208,Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore,"Asians who carry the HLA-B*1502 allele have an elevated risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with the antiepileptic drugs (AEDs) carbamazepine (CBZ) and phenytoin (PHT). With a focus on Singapore, this analysis identifies circumstances in which genotyping and targeted treatment with alternative AEDs that do not induce SJS/TEN is likely to be more cost-effective than 1) treatment with CBZ or PHT without genotyping or 2) providing a more expensive drug that does not induce SJS/TEN to all patients without genotyping.A decision tree model was developed in TreeAge. The model takes into account costs of epilepsy treatments and genotyping, reductions in quality of life and increased costs resulting from SJS/TEN complications, the prevalence of the risk allele, the positive predictive value (PPV) of genotyping, life expectancy, and other factors.Compared with no genotyping and providing CBZ to all, genotyping results in an incremental cost-effectiveness ratio of $37,030/quality-adjusted life year (QALY) for Chinese patients, $7,930/QALY for Malays, and $136,630/QALY for Indians in Singapore.Because of the different population allele frequencies of HLA-B*1502 among different ethnic groups, genotyping for HLA-B*1502 and providing alternate AEDs to those who test positive is cost-effective for Singaporean Chinese and Malays, but not for Singaporean Indians. Population frequency of HLA-B*1502, PPV, duration of treatment relative to life expectancy, and costs of alternative drugs are the key drivers influencing cost-effectiveness.",2012-01-09718,22955130,Neurology,Di Dong,2012,79 / 12,1259-67,No,22955130,"Di Dong; Cynthia Sung; Eric Andrew Finkelstein; Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore, Neurology, Sep/18/2012; 79(12):1526-632X; 1259-67",QALY,Singapore,Not Stated,Not Stated,Genotyping and providing valproate (VPA) for patients who test positive and carbamazepine (CBZ)/phenytoin (PTH) for patients who test negative vs. No genotyping and CBZ or PHT for all patients,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,7930,United States,2010,9412.13
10209,Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore,"Asians who carry the HLA-B*1502 allele have an elevated risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with the antiepileptic drugs (AEDs) carbamazepine (CBZ) and phenytoin (PHT). With a focus on Singapore, this analysis identifies circumstances in which genotyping and targeted treatment with alternative AEDs that do not induce SJS/TEN is likely to be more cost-effective than 1) treatment with CBZ or PHT without genotyping or 2) providing a more expensive drug that does not induce SJS/TEN to all patients without genotyping.A decision tree model was developed in TreeAge. The model takes into account costs of epilepsy treatments and genotyping, reductions in quality of life and increased costs resulting from SJS/TEN complications, the prevalence of the risk allele, the positive predictive value (PPV) of genotyping, life expectancy, and other factors.Compared with no genotyping and providing CBZ to all, genotyping results in an incremental cost-effectiveness ratio of $37,030/quality-adjusted life year (QALY) for Chinese patients, $7,930/QALY for Malays, and $136,630/QALY for Indians in Singapore.Because of the different population allele frequencies of HLA-B*1502 among different ethnic groups, genotyping for HLA-B*1502 and providing alternate AEDs to those who test positive is cost-effective for Singaporean Chinese and Malays, but not for Singaporean Indians. Population frequency of HLA-B*1502, PPV, duration of treatment relative to life expectancy, and costs of alternative drugs are the key drivers influencing cost-effectiveness.",2012-01-09718,22955130,Neurology,Di Dong,2012,79 / 12,1259-67,No,22955130,"Di Dong; Cynthia Sung; Eric Andrew Finkelstein; Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore, Neurology, Sep/18/2012; 79(12):1526-632X; 1259-67",QALY,Singapore,Not Stated,Not Stated,Genotyping and providing valproate (VPA) for patients who test positive and carbamazepine (CBZ)/phenytoin (PTH) for patients who test negative vs. No genotyping and CBZ or PHT for all patients,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,136630,United States,2010,162166.36
10210,Cost-effective treatment of low-risk carcinoma not invading bladder muscle,"Study Type - Therapy (cost effectiveness analysis) Level of Evidence 2a What''s known on the subject? and What does the study add? Bladder cancer is one of the costliest malignancies to treat throughout the life of a patient. The most cost-effective management for low-risk non-muscle-invasive bladder cancer is not known. The current study shows that employing cystoscopic office fulguration for low-risk appearing bladder cancer recurrences can materially impact the cost-effectiveness of therapy. In a follow-up protocol where office fulguration is routinely employed for low-risk bladder cancers, peri-operative intravesical chemotherapy may not provide any additional cost-effectiveness benefit. OBJECTIVE: To examine the cost-effectiveness of fulguration vs transurethral resection of bladder tumour (TURBT) with and without perioperative intravesical chemotherapy (PIC) for managing low-risk carcinoma not invading bladder muscle (NMIBC). Low-risk NMIBC carries a low progression rate, lending support to the use of office-based fulguration for small recurrences rather than traditional TURBT. MATERIALS AND METHODS: A Markov state transition model was created to simulate treatment of NMIBC with vs without PIC, with recurrence treated by formal TURBT vs treatment with fulguration. Costing data were obtained from the Medicare Resource Based Relative Value Scale. Data regarding the success of PIC were obtained from the peer-reviewed literature, as were corresponding utilities for bladder cancer-related procedures. Sensitivity analyses were performed. RESULTS: At 5-year follow-up, a strategy of fulguration without PIC was the most cost-effective (mean cost-effectiveness = US $654.8/quality-adjusted life year), despite a lower recurrence rate with PIC. Both fulguration strategies dominated each TURBT strategy. Sensitivity analysis showed that fulguration without PIC dominated all other strategies when the recurrence rate after PIC was increased to >/=14.2% per year. Similarly, the cost-effectiveness of TURBT becomes more competitive with fulguration when the total cost of TURBT declines < US $1175. CONCLUSIONS: The present study shows that fulguration without PIC was the most cost-effective strategy for treating low-risk NMIBC. The effectiveness of PIC and the cost of TURBT can materially impact the cost-effectiveness of the different management strategies. These results should be considered in treatment decisions in the context of preserving oncological control.",2012-01-09725,22958598,BJU Int,David A Green,2013,111 / 3 Pt B,,No,22958598,"David A Green; Michael Rink; Eugene K Cha; Evanguelos Xylinas; Bilal Chughtai; Douglas S Scherr; Shahrokh F Shariat; Richard K Lee; Cost-effective treatment of low-risk carcinoma not invading bladder muscle, BJU Int, 2013 Mar; 111(3 Pt B):1464-4096",QALY,Not Stated,Not Stated,Not Stated,Perioperative intravesical chemotherapy (PIC) + fulguration vs. Perioperative intravesical chemotherapy (PIC) + transurethral resection of bladder tumor (TURBT),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,-46720.5,United States,2010,-55452.63
10211,Cost-effective treatment of low-risk carcinoma not invading bladder muscle,"Study Type - Therapy (cost effectiveness analysis) Level of Evidence 2a What''s known on the subject? and What does the study add? Bladder cancer is one of the costliest malignancies to treat throughout the life of a patient. The most cost-effective management for low-risk non-muscle-invasive bladder cancer is not known. The current study shows that employing cystoscopic office fulguration for low-risk appearing bladder cancer recurrences can materially impact the cost-effectiveness of therapy. In a follow-up protocol where office fulguration is routinely employed for low-risk bladder cancers, peri-operative intravesical chemotherapy may not provide any additional cost-effectiveness benefit. OBJECTIVE: To examine the cost-effectiveness of fulguration vs transurethral resection of bladder tumour (TURBT) with and without perioperative intravesical chemotherapy (PIC) for managing low-risk carcinoma not invading bladder muscle (NMIBC). Low-risk NMIBC carries a low progression rate, lending support to the use of office-based fulguration for small recurrences rather than traditional TURBT. MATERIALS AND METHODS: A Markov state transition model was created to simulate treatment of NMIBC with vs without PIC, with recurrence treated by formal TURBT vs treatment with fulguration. Costing data were obtained from the Medicare Resource Based Relative Value Scale. Data regarding the success of PIC were obtained from the peer-reviewed literature, as were corresponding utilities for bladder cancer-related procedures. Sensitivity analyses were performed. RESULTS: At 5-year follow-up, a strategy of fulguration without PIC was the most cost-effective (mean cost-effectiveness = US $654.8/quality-adjusted life year), despite a lower recurrence rate with PIC. Both fulguration strategies dominated each TURBT strategy. Sensitivity analysis showed that fulguration without PIC dominated all other strategies when the recurrence rate after PIC was increased to >/=14.2% per year. Similarly, the cost-effectiveness of TURBT becomes more competitive with fulguration when the total cost of TURBT declines < US $1175. CONCLUSIONS: The present study shows that fulguration without PIC was the most cost-effective strategy for treating low-risk NMIBC. The effectiveness of PIC and the cost of TURBT can materially impact the cost-effectiveness of the different management strategies. These results should be considered in treatment decisions in the context of preserving oncological control.",2012-01-09725,22958598,BJU Int,David A Green,2013,111 / 3 Pt B,,No,22958598,"David A Green; Michael Rink; Eugene K Cha; Evanguelos Xylinas; Bilal Chughtai; Douglas S Scherr; Shahrokh F Shariat; Richard K Lee; Cost-effective treatment of low-risk carcinoma not invading bladder muscle, BJU Int, 2013 Mar; 111(3 Pt B):1464-4096",QALY,Not Stated,Not Stated,Not Stated,Perioperative intravesical chemotherapy (PIC) + fulguration vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,4169.24,United States,2010,4948.48
10212,Cost-effective treatment of low-risk carcinoma not invading bladder muscle,"Study Type - Therapy (cost effectiveness analysis) Level of Evidence 2a What''s known on the subject? and What does the study add? Bladder cancer is one of the costliest malignancies to treat throughout the life of a patient. The most cost-effective management for low-risk non-muscle-invasive bladder cancer is not known. The current study shows that employing cystoscopic office fulguration for low-risk appearing bladder cancer recurrences can materially impact the cost-effectiveness of therapy. In a follow-up protocol where office fulguration is routinely employed for low-risk bladder cancers, peri-operative intravesical chemotherapy may not provide any additional cost-effectiveness benefit. OBJECTIVE: To examine the cost-effectiveness of fulguration vs transurethral resection of bladder tumour (TURBT) with and without perioperative intravesical chemotherapy (PIC) for managing low-risk carcinoma not invading bladder muscle (NMIBC). Low-risk NMIBC carries a low progression rate, lending support to the use of office-based fulguration for small recurrences rather than traditional TURBT. MATERIALS AND METHODS: A Markov state transition model was created to simulate treatment of NMIBC with vs without PIC, with recurrence treated by formal TURBT vs treatment with fulguration. Costing data were obtained from the Medicare Resource Based Relative Value Scale. Data regarding the success of PIC were obtained from the peer-reviewed literature, as were corresponding utilities for bladder cancer-related procedures. Sensitivity analyses were performed. RESULTS: At 5-year follow-up, a strategy of fulguration without PIC was the most cost-effective (mean cost-effectiveness = US $654.8/quality-adjusted life year), despite a lower recurrence rate with PIC. Both fulguration strategies dominated each TURBT strategy. Sensitivity analysis showed that fulguration without PIC dominated all other strategies when the recurrence rate after PIC was increased to >/=14.2% per year. Similarly, the cost-effectiveness of TURBT becomes more competitive with fulguration when the total cost of TURBT declines < US $1175. CONCLUSIONS: The present study shows that fulguration without PIC was the most cost-effective strategy for treating low-risk NMIBC. The effectiveness of PIC and the cost of TURBT can materially impact the cost-effectiveness of the different management strategies. These results should be considered in treatment decisions in the context of preserving oncological control.",2012-01-09725,22958598,BJU Int,David A Green,2013,111 / 3 Pt B,,No,22958598,"David A Green; Michael Rink; Eugene K Cha; Evanguelos Xylinas; Bilal Chughtai; Douglas S Scherr; Shahrokh F Shariat; Richard K Lee; Cost-effective treatment of low-risk carcinoma not invading bladder muscle, BJU Int, 2013 Mar; 111(3 Pt B):1464-4096",QALY,Not Stated,Not Stated,Not Stated,Perioperative intravesical chemotherapy (PIC) + fulguration vs. Transurethral resection of bladder tumor (TURBT),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,-4176.75,United States,2010,-4957.39
10213,Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain,"INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System. METHODS: Adaptation of a Markov chain model that simulates the natural history of the disease over the lifetime of a cohort of 10?000 patients with non-valvular atrial fibrillation. Model comparators were warfarin in a first scenario, and a real world prescribing pattern in a second scenario, in which 60% of the patients were treated with vitamin K antagonists, 30% with acetylsalicylic acid, and 10% received no treatment. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: Dabigatran reduced the occurrence of clinical events in both scenarios, providing gains in quantity and quality of life. The incremental cost-effectiveness ratio for dabigatran compared to warfarin was 17 581 euros/quality-adjusted life year gained and 14 118 euros/quality-adjusted life year gained when compared to the real world prescribing pattern. Efficiency in subgroups was demonstrated. When the social costs were incorporated into the analysis, dabigatran was found to be a dominant strategy (ie, more effective and less costly). The model proved to be robust. CONCLUSIONS: From the perspective of the Spanish National Health System, dabigatran is an efficient strategy for the prevention of stroke in patients with non-valvular atrial fibrillation compared to warfarin and to the real-world prescribing pattern; incremental cost-effectiveness ratios were below the 30 000 euros/quality-adjusted life year threshold in both scenarios. Dabigatran would also be a dominant strategy from the societal perspective, providing society with a more effective therapy at a lower cost compared to the other 2 alternatives. Full English text available from:www.revespcardiol.org.",2012-01-09726,22958943,Rev Esp Cardiol,Jos? R Gonz?lez-Juanatey,2012,65 / 10,901-910,No,22958943,"Jos? R Gonz?lez-Juanatey; Jos? ?lvarez-Sabin; Jos? M Lobos; Antoni Mart?nez-Rubio; Joan C Reverter; Itziar Oyag?ez; Nuria Gonz?lez-Rojas; Virginia Becerra; Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain, Rev Esp Cardiol, ; 65(10):0300-8932; 901-910",QALY,Spain,Not Stated,Not Stated,Dabigatran (150-110 mg twice a day) vs. Warfarin,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,17581,Euro,2010,27616.05
10214,Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain,"INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System. METHODS: Adaptation of a Markov chain model that simulates the natural history of the disease over the lifetime of a cohort of 10?000 patients with non-valvular atrial fibrillation. Model comparators were warfarin in a first scenario, and a real world prescribing pattern in a second scenario, in which 60% of the patients were treated with vitamin K antagonists, 30% with acetylsalicylic acid, and 10% received no treatment. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: Dabigatran reduced the occurrence of clinical events in both scenarios, providing gains in quantity and quality of life. The incremental cost-effectiveness ratio for dabigatran compared to warfarin was 17 581 euros/quality-adjusted life year gained and 14 118 euros/quality-adjusted life year gained when compared to the real world prescribing pattern. Efficiency in subgroups was demonstrated. When the social costs were incorporated into the analysis, dabigatran was found to be a dominant strategy (ie, more effective and less costly). The model proved to be robust. CONCLUSIONS: From the perspective of the Spanish National Health System, dabigatran is an efficient strategy for the prevention of stroke in patients with non-valvular atrial fibrillation compared to warfarin and to the real-world prescribing pattern; incremental cost-effectiveness ratios were below the 30 000 euros/quality-adjusted life year threshold in both scenarios. Dabigatran would also be a dominant strategy from the societal perspective, providing society with a more effective therapy at a lower cost compared to the other 2 alternatives. Full English text available from:www.revespcardiol.org.",2012-01-09726,22958943,Rev Esp Cardiol,Jos? R Gonz?lez-Juanatey,2012,65 / 10,901-910,No,22958943,"Jos? R Gonz?lez-Juanatey; Jos? ?lvarez-Sabin; Jos? M Lobos; Antoni Mart?nez-Rubio; Joan C Reverter; Itziar Oyag?ez; Nuria Gonz?lez-Rojas; Virginia Becerra; Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain, Rev Esp Cardiol, ; 65(10):0300-8932; 901-910",QALY,Spain,Not Stated,Not Stated,Dabigatran (150-110 mg twice a day) vs. Real-world prescribing patterns,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,16967.65,Euro,2010,26652.6
10215,Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain,"INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System. METHODS: Adaptation of a Markov chain model that simulates the natural history of the disease over the lifetime of a cohort of 10?000 patients with non-valvular atrial fibrillation. Model comparators were warfarin in a first scenario, and a real world prescribing pattern in a second scenario, in which 60% of the patients were treated with vitamin K antagonists, 30% with acetylsalicylic acid, and 10% received no treatment. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: Dabigatran reduced the occurrence of clinical events in both scenarios, providing gains in quantity and quality of life. The incremental cost-effectiveness ratio for dabigatran compared to warfarin was 17 581 euros/quality-adjusted life year gained and 14 118 euros/quality-adjusted life year gained when compared to the real world prescribing pattern. Efficiency in subgroups was demonstrated. When the social costs were incorporated into the analysis, dabigatran was found to be a dominant strategy (ie, more effective and less costly). The model proved to be robust. CONCLUSIONS: From the perspective of the Spanish National Health System, dabigatran is an efficient strategy for the prevention of stroke in patients with non-valvular atrial fibrillation compared to warfarin and to the real-world prescribing pattern; incremental cost-effectiveness ratios were below the 30 000 euros/quality-adjusted life year threshold in both scenarios. Dabigatran would also be a dominant strategy from the societal perspective, providing society with a more effective therapy at a lower cost compared to the other 2 alternatives. Full English text available from:www.revespcardiol.org.",2012-01-09726,22958943,Rev Esp Cardiol,Jos? R Gonz?lez-Juanatey,2012,65 / 10,901-910,No,22958943,"Jos? R Gonz?lez-Juanatey; Jos? ?lvarez-Sabin; Jos? M Lobos; Antoni Mart?nez-Rubio; Joan C Reverter; Itziar Oyag?ez; Nuria Gonz?lez-Rojas; Virginia Becerra; Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain, Rev Esp Cardiol, ; 65(10):0300-8932; 901-910",QALY,Spain,Not Stated,Not Stated,Dabigatran (150-110 mg twice a day) vs. Warfarin,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,Not Stated,Euro,2010,Not Stated
10216,Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain,"INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System. METHODS: Adaptation of a Markov chain model that simulates the natural history of the disease over the lifetime of a cohort of 10?000 patients with non-valvular atrial fibrillation. Model comparators were warfarin in a first scenario, and a real world prescribing pattern in a second scenario, in which 60% of the patients were treated with vitamin K antagonists, 30% with acetylsalicylic acid, and 10% received no treatment. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: Dabigatran reduced the occurrence of clinical events in both scenarios, providing gains in quantity and quality of life. The incremental cost-effectiveness ratio for dabigatran compared to warfarin was 17 581 euros/quality-adjusted life year gained and 14 118 euros/quality-adjusted life year gained when compared to the real world prescribing pattern. Efficiency in subgroups was demonstrated. When the social costs were incorporated into the analysis, dabigatran was found to be a dominant strategy (ie, more effective and less costly). The model proved to be robust. CONCLUSIONS: From the perspective of the Spanish National Health System, dabigatran is an efficient strategy for the prevention of stroke in patients with non-valvular atrial fibrillation compared to warfarin and to the real-world prescribing pattern; incremental cost-effectiveness ratios were below the 30 000 euros/quality-adjusted life year threshold in both scenarios. Dabigatran would also be a dominant strategy from the societal perspective, providing society with a more effective therapy at a lower cost compared to the other 2 alternatives. Full English text available from:www.revespcardiol.org.",2012-01-09726,22958943,Rev Esp Cardiol,Jos? R Gonz?lez-Juanatey,2012,65 / 10,901-910,No,22958943,"Jos? R Gonz?lez-Juanatey; Jos? ?lvarez-Sabin; Jos? M Lobos; Antoni Mart?nez-Rubio; Joan C Reverter; Itziar Oyag?ez; Nuria Gonz?lez-Rojas; Virginia Becerra; Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain, Rev Esp Cardiol, ; 65(10):0300-8932; 901-910",QALY,Spain,Not Stated,Not Stated,Dabigatran (150-110 mg twice a day) vs. Real world prescribing patterns,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,Not Stated,Euro,2010,Not Stated
10217,The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop,"BACKGROUND: The txt2stop trial has shown that mobile-phone-based smoking cessation support doubles biochemically validated quitting at 6 months. This study examines the cost-effectiveness of smoking cessation support delivered by mobile phone text messaging. METHODS: The lifetime incremental costs and benefits of adding text-based support to current practice are estimated from a UK NHS perspective using a Markov model. The cost-effectiveness was measured in terms of cost per quitter, cost per life year gained and cost per QALY gained. As in previous studies, smokers are assumed to face a higher risk of experiencing the following five diseases: lung cancer, stroke, myocardial infarction, chronic obstructive pulmonary disease, and coronary heart disease (i.e. the main fatal or disabling, but by no means the only, adverse effects of prolonged smoking). The treatment costs and health state values associated with these diseases were identified from the literature. The analysis was based on the age and gender distribution observed in the txt2stop trial. Effectiveness and cost parameters were varied in deterministic sensitivity analyses, and a probabilistic sensitivity analysis was also performed. FINDINGS: The cost of text-based support per 1,000 enrolled smokers is pound16,120, which, given an estimated 58 additional quitters at 6 months, equates to pound278 per quitter. However, when the future NHS costs saved (as a result of reduced smoking) are included, text-based support would be cost saving. It is estimated that 18 LYs are gained per 1,000 smokers (0.3 LYs per quitter) receiving text-based support, and 29 QALYs are gained (0.5 QALYs per quitter). The deterministic sensitivity analysis indicated that changes in individual model parameters did not alter the conclusion that this is a cost-effective intervention. Similarly, the probabilistic sensitivity analysis indicated a >90 % chance that the intervention will be cost saving. INTERPRETATION: This study shows that under a wide variety of conditions, personalised smoking cessation advice and support by mobile phone message is both beneficial for health and cost saving to a health system.",2012-01-09731,22961230,Eur J Health Econ,Carla Guerriero,2013,14 / 5,,Yes,22961230,"Carla Guerriero; John Cairns; Ian Roberts; Anthony Rodgers; Robyn Whittaker; Caroline Free; The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop, Eur J Health Econ, 2013 Oct; 14(5):1618-7598",QALY,Not Stated,Not Stated,Not Stated,"Text-based support for smoking cessation in addition to current practices vs. Current practices for smoking cessation (a mix of interventions, such as nicotine replacement therapy, telephone helpline)",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,-1431.34,United Kingdom,2009,-2500.18
10218,The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop,"BACKGROUND: The txt2stop trial has shown that mobile-phone-based smoking cessation support doubles biochemically validated quitting at 6 months. This study examines the cost-effectiveness of smoking cessation support delivered by mobile phone text messaging. METHODS: The lifetime incremental costs and benefits of adding text-based support to current practice are estimated from a UK NHS perspective using a Markov model. The cost-effectiveness was measured in terms of cost per quitter, cost per life year gained and cost per QALY gained. As in previous studies, smokers are assumed to face a higher risk of experiencing the following five diseases: lung cancer, stroke, myocardial infarction, chronic obstructive pulmonary disease, and coronary heart disease (i.e. the main fatal or disabling, but by no means the only, adverse effects of prolonged smoking). The treatment costs and health state values associated with these diseases were identified from the literature. The analysis was based on the age and gender distribution observed in the txt2stop trial. Effectiveness and cost parameters were varied in deterministic sensitivity analyses, and a probabilistic sensitivity analysis was also performed. FINDINGS: The cost of text-based support per 1,000 enrolled smokers is pound16,120, which, given an estimated 58 additional quitters at 6 months, equates to pound278 per quitter. However, when the future NHS costs saved (as a result of reduced smoking) are included, text-based support would be cost saving. It is estimated that 18 LYs are gained per 1,000 smokers (0.3 LYs per quitter) receiving text-based support, and 29 QALYs are gained (0.5 QALYs per quitter). The deterministic sensitivity analysis indicated that changes in individual model parameters did not alter the conclusion that this is a cost-effective intervention. Similarly, the probabilistic sensitivity analysis indicated a >90 % chance that the intervention will be cost saving. INTERPRETATION: This study shows that under a wide variety of conditions, personalised smoking cessation advice and support by mobile phone message is both beneficial for health and cost saving to a health system.",2012-01-09731,22961230,Eur J Health Econ,Carla Guerriero,2013,14 / 5,,Yes,22961230,"Carla Guerriero; John Cairns; Ian Roberts; Anthony Rodgers; Robyn Whittaker; Caroline Free; The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop, Eur J Health Econ, 2013 Oct; 14(5):1618-7598",QALY,Not Stated,Not Stated,Not Stated,"Text-based support for smoking cessation in addition to current practices vs. Current practices for smoking cessation (a mix of interventions, such as nicotine replacement therapy, telephone helpline)",Not Stated,29 Years,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,-553.3,United Kingdom,2009,-966.47
10219,The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop,"BACKGROUND: The txt2stop trial has shown that mobile-phone-based smoking cessation support doubles biochemically validated quitting at 6 months. This study examines the cost-effectiveness of smoking cessation support delivered by mobile phone text messaging. METHODS: The lifetime incremental costs and benefits of adding text-based support to current practice are estimated from a UK NHS perspective using a Markov model. The cost-effectiveness was measured in terms of cost per quitter, cost per life year gained and cost per QALY gained. As in previous studies, smokers are assumed to face a higher risk of experiencing the following five diseases: lung cancer, stroke, myocardial infarction, chronic obstructive pulmonary disease, and coronary heart disease (i.e. the main fatal or disabling, but by no means the only, adverse effects of prolonged smoking). The treatment costs and health state values associated with these diseases were identified from the literature. The analysis was based on the age and gender distribution observed in the txt2stop trial. Effectiveness and cost parameters were varied in deterministic sensitivity analyses, and a probabilistic sensitivity analysis was also performed. FINDINGS: The cost of text-based support per 1,000 enrolled smokers is pound16,120, which, given an estimated 58 additional quitters at 6 months, equates to pound278 per quitter. However, when the future NHS costs saved (as a result of reduced smoking) are included, text-based support would be cost saving. It is estimated that 18 LYs are gained per 1,000 smokers (0.3 LYs per quitter) receiving text-based support, and 29 QALYs are gained (0.5 QALYs per quitter). The deterministic sensitivity analysis indicated that changes in individual model parameters did not alter the conclusion that this is a cost-effective intervention. Similarly, the probabilistic sensitivity analysis indicated a >90 % chance that the intervention will be cost saving. INTERPRETATION: This study shows that under a wide variety of conditions, personalised smoking cessation advice and support by mobile phone message is both beneficial for health and cost saving to a health system.",2012-01-09731,22961230,Eur J Health Econ,Carla Guerriero,2013,14 / 5,,Yes,22961230,"Carla Guerriero; John Cairns; Ian Roberts; Anthony Rodgers; Robyn Whittaker; Caroline Free; The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop, Eur J Health Econ, 2013 Oct; 14(5):1618-7598",QALY,Not Stated,Not Stated,Not Stated,"Text-based support for smoking cessation in addition to current practices vs. Current practices for smoking cessation (a mix of interventions, such as nicotine replacement therapy, telephone helpline)",Not Stated,40 Years,30 Years,"Female, Male",Full,Lifetime,3.50,3.50,-1122.96,United Kingdom,2009,-1961.52
10220,The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop,"BACKGROUND: The txt2stop trial has shown that mobile-phone-based smoking cessation support doubles biochemically validated quitting at 6 months. This study examines the cost-effectiveness of smoking cessation support delivered by mobile phone text messaging. METHODS: The lifetime incremental costs and benefits of adding text-based support to current practice are estimated from a UK NHS perspective using a Markov model. The cost-effectiveness was measured in terms of cost per quitter, cost per life year gained and cost per QALY gained. As in previous studies, smokers are assumed to face a higher risk of experiencing the following five diseases: lung cancer, stroke, myocardial infarction, chronic obstructive pulmonary disease, and coronary heart disease (i.e. the main fatal or disabling, but by no means the only, adverse effects of prolonged smoking). The treatment costs and health state values associated with these diseases were identified from the literature. The analysis was based on the age and gender distribution observed in the txt2stop trial. Effectiveness and cost parameters were varied in deterministic sensitivity analyses, and a probabilistic sensitivity analysis was also performed. FINDINGS: The cost of text-based support per 1,000 enrolled smokers is pound16,120, which, given an estimated 58 additional quitters at 6 months, equates to pound278 per quitter. However, when the future NHS costs saved (as a result of reduced smoking) are included, text-based support would be cost saving. It is estimated that 18 LYs are gained per 1,000 smokers (0.3 LYs per quitter) receiving text-based support, and 29 QALYs are gained (0.5 QALYs per quitter). The deterministic sensitivity analysis indicated that changes in individual model parameters did not alter the conclusion that this is a cost-effective intervention. Similarly, the probabilistic sensitivity analysis indicated a >90 % chance that the intervention will be cost saving. INTERPRETATION: This study shows that under a wide variety of conditions, personalised smoking cessation advice and support by mobile phone message is both beneficial for health and cost saving to a health system.",2012-01-09731,22961230,Eur J Health Econ,Carla Guerriero,2013,14 / 5,,Yes,22961230,"Carla Guerriero; John Cairns; Ian Roberts; Anthony Rodgers; Robyn Whittaker; Caroline Free; The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop, Eur J Health Econ, 2013 Oct; 14(5):1618-7598",QALY,Not Stated,Not Stated,Not Stated,"Text-based support for smoking cessation in addition to current practices vs. Current practices for smoking cessation (a mix of interventions, such as nicotine replacement therapy, telephone helpline)",Not Stated,Not Stated,41 Years,"Female, Male",Full,Lifetime,3.50,3.50,-1953,United Kingdom,2009,-3411.38
10221,Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement,"Generally dismal outcomes have led to a nihilistic attitude toward treating pancreatic cancer, while fiscal constraints have increased scrutiny of treatments costs. Our objective was to compare the cost-effectiveness of various treatment strategies for resectable pancreatic head adenocarcinoma, and to identify opportunities for improved cost effectiveness.A decision model compared 6 strategies: no treatment, radiotherapy only, chemotherapy only, chemotherapy plus radiotherapy, surgery alone, and surgery plus adjuvant therapy. Outcomes and probabilities were identified using the National Cancer Data Base, the American Cancer Society National Surgical Quality Improvement Program, and the literature. Costs were estimated using Medicare payment. Incremental cost-effectiveness ratios (ICERs) were calculated, and sensitivity analyses were performed by varying potentially modifiable parameters of the model. Survival was reported in quality-adjusted life-months (QALMs).Surgery plus adjuvant therapy, chemotherapy alone, and no treatment were the only viable strategies in terms of cost effectiveness. Surgery plus adjuvant therapy versus no treatment demonstrated an incremental cost-effectiveness ratio (ICER) of $7,663/QALM. Theoretically increasing survival in node-negative, margin-negative patients from 14 to 22 QALMs produced the largest reduction in the ICER for surgery plus adjuvant therapy compared to no treatment ($6,386/QALM), whereas reducing the perioperative mortality from 3 to 1?% had only a marginal effect. The ICER was significantly lower for high-performing centers ($5,991/QALM) than for low-performing centers ($9,144/QALM).Surgery plus adjuvant therapy for resectable pancreatic head adenocarcinoma extends survival, but at considerable expense. Significant cost reductions could be realized by improving treatment outcomes to levels of high-performing centers and development of increasingly effective adjuvant therapies.",2012-01-09736,22965567,Ann Surg Oncol,Daniel E Abbott,2012,19 / 12,3659-67,No,22965567,"Daniel E Abbott; Ryan P Merkow; Scott B Cantor; Jason B Fleming; Gauri R Varadhachary; Christopher Crane; David J Bentrem; Karl Y Bilimoria; Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement, Ann Surg Oncol, ; 19(12):1068-9265; 3659-67",QALY,Not Stated,Not Stated,Not Stated,Chemotherapy alone (gemcitabine 600mg per m.sq. concurrent with cisplatin 30 mg per m.sq. both 3 times per month for 4 months) vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,36264,United States,2011,41724.74
10222,Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement,"Generally dismal outcomes have led to a nihilistic attitude toward treating pancreatic cancer, while fiscal constraints have increased scrutiny of treatments costs. Our objective was to compare the cost-effectiveness of various treatment strategies for resectable pancreatic head adenocarcinoma, and to identify opportunities for improved cost effectiveness.A decision model compared 6 strategies: no treatment, radiotherapy only, chemotherapy only, chemotherapy plus radiotherapy, surgery alone, and surgery plus adjuvant therapy. Outcomes and probabilities were identified using the National Cancer Data Base, the American Cancer Society National Surgical Quality Improvement Program, and the literature. Costs were estimated using Medicare payment. Incremental cost-effectiveness ratios (ICERs) were calculated, and sensitivity analyses were performed by varying potentially modifiable parameters of the model. Survival was reported in quality-adjusted life-months (QALMs).Surgery plus adjuvant therapy, chemotherapy alone, and no treatment were the only viable strategies in terms of cost effectiveness. Surgery plus adjuvant therapy versus no treatment demonstrated an incremental cost-effectiveness ratio (ICER) of $7,663/QALM. Theoretically increasing survival in node-negative, margin-negative patients from 14 to 22 QALMs produced the largest reduction in the ICER for surgery plus adjuvant therapy compared to no treatment ($6,386/QALM), whereas reducing the perioperative mortality from 3 to 1?% had only a marginal effect. The ICER was significantly lower for high-performing centers ($5,991/QALM) than for low-performing centers ($9,144/QALM).Surgery plus adjuvant therapy for resectable pancreatic head adenocarcinoma extends survival, but at considerable expense. Significant cost reductions could be realized by improving treatment outcomes to levels of high-performing centers and development of increasingly effective adjuvant therapies.",2012-01-09736,22965567,Ann Surg Oncol,Daniel E Abbott,2012,19 / 12,3659-67,No,22965567,"Daniel E Abbott; Ryan P Merkow; Scott B Cantor; Jason B Fleming; Gauri R Varadhachary; Christopher Crane; David J Bentrem; Karl Y Bilimoria; Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement, Ann Surg Oncol, ; 19(12):1068-9265; 3659-67",QALY,Not Stated,Not Stated,Not Stated,"Surgery plus adjuvant chemotherapy (gemcitabine 1000 mg per m.sq, 3 infusions per month for 6 months) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,91956,United States,2011,105803.01
10223,Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement,"Generally dismal outcomes have led to a nihilistic attitude toward treating pancreatic cancer, while fiscal constraints have increased scrutiny of treatments costs. Our objective was to compare the cost-effectiveness of various treatment strategies for resectable pancreatic head adenocarcinoma, and to identify opportunities for improved cost effectiveness.A decision model compared 6 strategies: no treatment, radiotherapy only, chemotherapy only, chemotherapy plus radiotherapy, surgery alone, and surgery plus adjuvant therapy. Outcomes and probabilities were identified using the National Cancer Data Base, the American Cancer Society National Surgical Quality Improvement Program, and the literature. Costs were estimated using Medicare payment. Incremental cost-effectiveness ratios (ICERs) were calculated, and sensitivity analyses were performed by varying potentially modifiable parameters of the model. Survival was reported in quality-adjusted life-months (QALMs).Surgery plus adjuvant therapy, chemotherapy alone, and no treatment were the only viable strategies in terms of cost effectiveness. Surgery plus adjuvant therapy versus no treatment demonstrated an incremental cost-effectiveness ratio (ICER) of $7,663/QALM. Theoretically increasing survival in node-negative, margin-negative patients from 14 to 22 QALMs produced the largest reduction in the ICER for surgery plus adjuvant therapy compared to no treatment ($6,386/QALM), whereas reducing the perioperative mortality from 3 to 1?% had only a marginal effect. The ICER was significantly lower for high-performing centers ($5,991/QALM) than for low-performing centers ($9,144/QALM).Surgery plus adjuvant therapy for resectable pancreatic head adenocarcinoma extends survival, but at considerable expense. Significant cost reductions could be realized by improving treatment outcomes to levels of high-performing centers and development of increasingly effective adjuvant therapies.",2012-01-09736,22965567,Ann Surg Oncol,Daniel E Abbott,2012,19 / 12,3659-67,No,22965567,"Daniel E Abbott; Ryan P Merkow; Scott B Cantor; Jason B Fleming; Gauri R Varadhachary; Christopher Crane; David J Bentrem; Karl Y Bilimoria; Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement, Ann Surg Oncol, ; 19(12):1068-9265; 3659-67",QALY,Not Stated,Not Stated,Not Stated,Surgery plus adjuvant chemotherapy vs. Chemotherapy alone (gemcitabine 600mg per m.sq. concurrent with cisplatin 30 mg per m.sq. both 3 times per month for 4 months),Not Stated,Not Stated,Not Stated,"Female, Male",Full,12 Months,Not Stated,Not Stated,133404,United States,2011,153492.38
10224,"Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial","The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19,967.00 for PCI; and $18,263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16,553.00, $25,831.00, and $24,614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05).In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI.www.controlled-trials.com. Registration number: ISRCTN66068876.",2012-01-09737,22965975,Circulation,Ricardo D'Oliveira Vieira,2012,126 / 11Suppl1,S145-50,No,22965975,"Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rog?rio Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; Jos? Antonio Franchini Ramires; Roberto Kalil Filho; Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial, Circulation, Sep/11/2012; 126(11Suppl1):0009-7322; S145-50",QALY,Not Stated,Not Stated,Not Stated,Coronary artery bypass surgery (CABG) vs. Percutaneous coronary intervention (PCI),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,-2103.7,United States,2009,-2537.84
10225,"Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial","The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19,967.00 for PCI; and $18,263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16,553.00, $25,831.00, and $24,614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05).In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI.www.controlled-trials.com. Registration number: ISRCTN66068876.",2012-01-09737,22965975,Circulation,Ricardo D'Oliveira Vieira,2012,126 / 11Suppl1,S145-50,No,22965975,"Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rog?rio Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; Jos? Antonio Franchini Ramires; Roberto Kalil Filho; Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial, Circulation, Sep/11/2012; 126(11Suppl1):0009-7322; S145-50",QALY,Not Stated,Not Stated,Not Stated,Coronary artery bypass surgery (CABG) vs. Medical treatment alone (MT),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,15068.85,United States,2009,18178.61
10226,"Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial","The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19,967.00 for PCI; and $18,263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16,553.00, $25,831.00, and $24,614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05).In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI.www.controlled-trials.com. Registration number: ISRCTN66068876.",2012-01-09737,22965975,Circulation,Ricardo D'Oliveira Vieira,2012,126 / 11Suppl1,S145-50,No,22965975,"Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rog?rio Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; Jos? Antonio Franchini Ramires; Roberto Kalil Filho; Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial, Circulation, Sep/11/2012; 126(11Suppl1):0009-7322; S145-50",QALY,Not Stated,Not Stated,Not Stated,Percutaneous coronary intervention (PCI) vs. Medical treatment alone (MT),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,-54480,United States,2009,-65723.04
10227,"Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial","The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19,967.00 for PCI; and $18,263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16,553.00, $25,831.00, and $24,614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05).In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI.www.controlled-trials.com. Registration number: ISRCTN66068876.",2012-01-09737,22965975,Circulation,Ricardo D'Oliveira Vieira,2012,126 / 11Suppl1,S145-50,No,22965975,"Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rog?rio Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; Jos? Antonio Franchini Ramires; Roberto Kalil Filho; Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial, Circulation, Sep/11/2012; 126(11Suppl1):0009-7322; S145-50",QALY,Not Stated,Not Stated,Not Stated,Coronary artery bypass graft (CABG) vs. Percutaneous coronary intervention (PCI),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,-30425,United States,2009,-36703.81
10228,"Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial","The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19,967.00 for PCI; and $18,263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16,553.00, $25,831.00, and $24,614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05).In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI.www.controlled-trials.com. Registration number: ISRCTN66068876.",2012-01-09737,22965975,Circulation,Ricardo D'Oliveira Vieira,2012,126 / 11Suppl1,S145-50,No,22965975,"Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rog?rio Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; Jos? Antonio Franchini Ramires; Roberto Kalil Filho; Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial, Circulation, Sep/11/2012; 126(11Suppl1):0009-7322; S145-50",QALY,Not Stated,Not Stated,Not Stated,Coronary artery bypass graft (CABG) vs. Medical treatment alone (MT),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,10893.24,United States,2009,13141.28
10229,"Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial","The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies.We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19,967.00 for PCI; and $18,263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P<0.01) and versus CABG (P<0.01) and CABG versus PCI (P=0.01). The event-free plus angina-free costs were $16,553.00, $25,831.00, and $24,614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P=0.04), and versus CABG (P<0.001); there was no difference between CABG and PCI (P>0.05).In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI.www.controlled-trials.com. Registration number: ISRCTN66068876.",2012-01-09737,22965975,Circulation,Ricardo D'Oliveira Vieira,2012,126 / 11Suppl1,S145-50,No,22965975,"Ricardo D'Oliveira Vieira; Whady Hueb; Mark Hlatky; Desiderio Favarato; Paulo Cury Rezende; Cibele Larrosa Garzillo; Eduardo Gomes Lima; Paulo Rog?rio Soares; Alexandre Ciappina Hueb; Alexandre Costa Pereira; Jos? Antonio Franchini Ramires; Roberto Kalil Filho; Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial, Circulation, Sep/11/2012; 126(11Suppl1):0009-7322; S145-50",QALY,Not Stated,Not Stated,Not Stated,Percutaneous coronary intervention (PCI) vs. Medical treatment alone (MT),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,13254.29,United States,2009,15989.57
10230,Economic evaluation of a weight control program with e-mail and telephone counseling among overweight employees: a randomized controlled trial,"ABSTRACT:Distance lifestyle counseling for weight control is a promising public health intervention in the work setting. Information about the cost-effectiveness of such interventions is lacking, but necessary to make informed implementation decisions. The purpose of this study was to perform an economic evaluation of a six-month program with lifestyle counseling aimed at weight reduction in an overweight working population with a two-year time horizon from a societal perspective.A randomized controlled trial comparing a program with two modes of intervention delivery against self-help. 1386 Employees from seven companies participated (67% male, mean age 43 (SD 8.6) years, mean BMI 29.6 (SD 3.5) kg/m2). All groups received self-directed lifestyle brochures. The two intervention groups additionally received a workbook-based program with phone counseling (phone; n=462) or a web-based program with e-mail counseling (internet; n=464). Body weight was measured at baseline and 24 months after baseline. Quality of life (EuroQol-5D) was assessed at baseline, 6, 12, 18 and 24 months after baseline. Resource use was measured with six-monthly diaries and valued with Dutch standard costs. Missing data were multiply imputed. Uncertainty around differences in costs and incremental cost-effectiveness ratios was estimated by applying non-parametric bootstrapping techniques and graphically plotting the results in cost-effectiveness planes and cost-effectiveness acceptability curves.At two years the incremental cost-effectiveness ratio was ?1009/kg weight loss in the phone group and ?16/kg weight loss in the internet group. The cost-utility analysis resulted in ?245,243/quality adjusted life year (QALY) and ?1337/QALY, respectively. The results from a complete-case analysis were slightly more favorable. However, there was considerable uncertainty around all outcomes.Neither intervention mode was proven to be cost-effective compared to self-help.ISRCTN04265725.",2012-01-09741,22967224,Int J Behav Nutr Phys Act,Marieke F van Wier,2012,9 /,112,No,22967224,"Marieke F van Wier; J Caroline Dekkers; Judith E Bosmans; Martijn W Heymans; Ingrid Jm Hendriksen; Nicolaas P Pronk; Willem van Mechelen; Maurits W van Tulder; Economic evaluation of a weight control program with e-mail and telephone counseling among overweight employees: a randomized controlled trial, Int J Behav Nutr Phys Act, ; 9():1479-5868; 112",QALY,Netherlands,Not Stated,Not Stated,"Phone-based lifestyle intervention program with modules on nutrition, physical activity, and behavior modification strategies vs. Control group receiving self-help brochures on lifestyle change",Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,Not Stated,Not Stated,1337,Euro,2004,2278.44
10231,Economic evaluation of a weight control program with e-mail and telephone counseling among overweight employees: a randomized controlled trial,"ABSTRACT:Distance lifestyle counseling for weight control is a promising public health intervention in the work setting. Information about the cost-effectiveness of such interventions is lacking, but necessary to make informed implementation decisions. The purpose of this study was to perform an economic evaluation of a six-month program with lifestyle counseling aimed at weight reduction in an overweight working population with a two-year time horizon from a societal perspective.A randomized controlled trial comparing a program with two modes of intervention delivery against self-help. 1386 Employees from seven companies participated (67% male, mean age 43 (SD 8.6) years, mean BMI 29.6 (SD 3.5) kg/m2). All groups received self-directed lifestyle brochures. The two intervention groups additionally received a workbook-based program with phone counseling (phone; n=462) or a web-based program with e-mail counseling (internet; n=464). Body weight was measured at baseline and 24 months after baseline. Quality of life (EuroQol-5D) was assessed at baseline, 6, 12, 18 and 24 months after baseline. Resource use was measured with six-monthly diaries and valued with Dutch standard costs. Missing data were multiply imputed. Uncertainty around differences in costs and incremental cost-effectiveness ratios was estimated by applying non-parametric bootstrapping techniques and graphically plotting the results in cost-effectiveness planes and cost-effectiveness acceptability curves.At two years the incremental cost-effectiveness ratio was ?1009/kg weight loss in the phone group and ?16/kg weight loss in the internet group. The cost-utility analysis resulted in ?245,243/quality adjusted life year (QALY) and ?1337/QALY, respectively. The results from a complete-case analysis were slightly more favorable. However, there was considerable uncertainty around all outcomes.Neither intervention mode was proven to be cost-effective compared to self-help.ISRCTN04265725.",2012-01-09741,22967224,Int J Behav Nutr Phys Act,Marieke F van Wier,2012,9 /,112,No,22967224,"Marieke F van Wier; J Caroline Dekkers; Judith E Bosmans; Martijn W Heymans; Ingrid Jm Hendriksen; Nicolaas P Pronk; Willem van Mechelen; Maurits W van Tulder; Economic evaluation of a weight control program with e-mail and telephone counseling among overweight employees: a randomized controlled trial, Int J Behav Nutr Phys Act, ; 9():1479-5868; 112",QALY,Netherlands,Not Stated,Not Stated,"Internet-based lifestyle intervention program with modules on nutrition, physical activity, and behavior modification strategies vs. Control group receiving self-help brochures on lifestyle change",Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,Not Stated,Not Stated,351999.97,Euro,2004,599859.78
10232,Comparative cost-effectiveness analysis of descemet stripping automated endothelial keratoplasty versus penetrating keratoplasty in the United States,"PURPOSE: To perform a comparative cost-effectiveness analysis of Descemet stripping automated endothelial keratoplasty (DSAEK) and penetrating keratoplasty (PK) for corneal endothelial disease. DESIGN: Retrospective cost-effectiveness analysis. METHODS: This cost-effectiveness analysis was performed from a third-party payer perspective with a 5-year time horizon. Probabilities of outcomes and complications of each of the procedures were calculated based on review of the published literature. A model was constructed to compare the costs and utilities associated with DSAEK and PK. Costs of donor tissue preparation, surgery, follow-up, postoperative complications, and procedures were considered. Utility values were based on quality-adjusted life years associated with visual acuity outcomes. Both costs and utilities were discounted at 3% per year. Sensitivity analyses were performed on key model inputs. RESULTS: Base case analysis found DSAEK to be less costly compared with PK ($9362 vs $10 239), with greater utility (3.15 vs 2.47 quality-adjusted life years). Sensitivity analyses revealed that even at graft failure rates for DSAEK approaching the rates for PK, DSAEK would still reduce costs. Varying the dislocation rate in our model showed that even at dislocation rates approaching 50%, DSAEK remained less costly. Further, with DSAEK rejection rates as high as 28%, DSAEK would remain a dominant procedure over PK. CONCLUSIONS: Comparative cost-effectiveness analysis of DSAEK versus PK indicates favorable cost and utility outcomes associated with DSAEK for treatment of corneal endothelial disease. Longer follow-up of DSAEK outcomes will provide more accurate information regarding long-term cost-effectiveness of the procedure.",2012-01-09743,22967866,Am J Ophthalmol,Shreya S Prabhu,2013,155 / 1,,No,22967866,"Shreya S Prabhu; Rola Kaakeh; Alan Sugar; Dean G Smith; Roni M Shtein; Comparative cost-effectiveness analysis of descemet stripping automated endothelial keratoplasty versus penetrating keratoplasty in the United States, Am J Ophthalmol, 2013 Jan; 155(1):0002-9394",QALY,Not Stated,Not Stated,Not Stated,Descement stripping automated endothelial keratoplasty (DSAEK) vs. Penetrating keratoplasty (PK),Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,-1289.71,United States,2010,-1530.75
10233,Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan,"Patients who require prolonged mechanical ventilation (PMV) are increasing and producing financial burdens worldwide. This study determines the cost per QALY (quality-adjusted life year), out-of-pocket expenses, and lifetime costs for PMV patients stratified by underlying diseases and cognition levels.A nationwide sample of 50,481 patients with continual mechanical ventilation for more than 21 days was collected during 1997-2007. After stratifying the patients according to specific diagnoses, a latent class analysis (LCA) was performed to categorise PMV patients with multiple co-morbidities into several homogeneous groups. The survival functions were estimated for individual groups using the Kaplan-Meier method and extrapolated to 300 months through a semi-parametric method. The survival functions were adjusted using an EQ-5D utility value derived from a convenience sample of 142 PMV patients to estimate quality-adjusted life expectancies (QALE). Another convenience sample of 165 patients was used to estimate the out-of-pocket expenses. The lifetime expenditures paid by the single-payer National Health Insurance (NHI) system and patients' families were estimated by multiplying average monthly expenditures by the survival probabilities and summing the values over lifetime.PMV therapy costs more than 100,000 U.S. dollars (USD) per QALY for all patients with poor cognition. For patients with partial cognition, PMV therapy costs less than 56,000 USD per QALY for those with liver cirrhosis, intracranial or spinal cord injuries, and 57,000-69,000 USD for patients with multiple co-morbidities under age of 65. The average lifetime cost of PMV was usually below 56,000 USD. The out-of-pocket expenses were often more than one-third of the total cost of treatment.PMV treatment for patients with poor cognition would cost more than 5 times Taiwan's GDP (gross domestic products), or less cost-effective. The out-of-pocket expenses for PMV provision should also be considered in policy decision.",2012-01-09747,22970160,PLoS One,Mei-Chuan Hung,2012,7 / 9,e44043,No,22970160,"Mei-Chuan Hung; Hsin-Ming Lu; Likwang Chen; Ming-Shian Lin; Cheng-Ren Chen; Chong-Jen Yu; Jung-Der Wang; Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan, PLoS One , ; 7(9):1932-6203; e44043",QALY,Not Stated,Not Stated,Not Stated,Prolonged mechanical ventilation (>21 days) vs. None (no reference group available),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,68089,United States,2010,80814.94
10234,Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan,"Patients who require prolonged mechanical ventilation (PMV) are increasing and producing financial burdens worldwide. This study determines the cost per QALY (quality-adjusted life year), out-of-pocket expenses, and lifetime costs for PMV patients stratified by underlying diseases and cognition levels.A nationwide sample of 50,481 patients with continual mechanical ventilation for more than 21 days was collected during 1997-2007. After stratifying the patients according to specific diagnoses, a latent class analysis (LCA) was performed to categorise PMV patients with multiple co-morbidities into several homogeneous groups. The survival functions were estimated for individual groups using the Kaplan-Meier method and extrapolated to 300 months through a semi-parametric method. The survival functions were adjusted using an EQ-5D utility value derived from a convenience sample of 142 PMV patients to estimate quality-adjusted life expectancies (QALE). Another convenience sample of 165 patients was used to estimate the out-of-pocket expenses. The lifetime expenditures paid by the single-payer National Health Insurance (NHI) system and patients' families were estimated by multiplying average monthly expenditures by the survival probabilities and summing the values over lifetime.PMV therapy costs more than 100,000 U.S. dollars (USD) per QALY for all patients with poor cognition. For patients with partial cognition, PMV therapy costs less than 56,000 USD per QALY for those with liver cirrhosis, intracranial or spinal cord injuries, and 57,000-69,000 USD for patients with multiple co-morbidities under age of 65. The average lifetime cost of PMV was usually below 56,000 USD. The out-of-pocket expenses were often more than one-third of the total cost of treatment.PMV treatment for patients with poor cognition would cost more than 5 times Taiwan's GDP (gross domestic products), or less cost-effective. The out-of-pocket expenses for PMV provision should also be considered in policy decision.",2012-01-09747,22970160,PLoS One,Mei-Chuan Hung,2012,7 / 9,e44043,No,22970160,"Mei-Chuan Hung; Hsin-Ming Lu; Likwang Chen; Ming-Shian Lin; Cheng-Ren Chen; Chong-Jen Yu; Jung-Der Wang; Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan, PLoS One , ; 7(9):1932-6203; e44043",QALY,Not Stated,Not Stated,Not Stated,Prolonged mechanical ventilation (>21 days) vs. None (no reference group available),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,134730,United States,2010,159911.24
10235,The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial,"BACKGROUND: The President''s National HIV/AIDS Strategy calls for coupling HIV screening and prevention services with substance abuse treatment programs. Fewer than half of US community-based substance abuse treatment programs make HIV testing available on-site or through referral. METHODS: We measured the cost-effectiveness of three HIV testing strategies evaluated in a randomized trial conducted in 12 community-based substance abuse treatment programs in 2009: off-site testing referral, on-site rapid testing with information only, on-site rapid testing with risk-reduction counseling. Data from the trial included patient demographics, prior testing history, test acceptance and receipt of results, undiagnosed HIV prevalence (0.4%) and program costs. The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) computer simulation model was used to project life expectancy, lifetime costs, and quality-adjusted life years (QALYs) for HIV-infected individuals. Incremental cost-effectiveness ratios (2009 US $/QALY) were calculated after adding costs of testing HIV-uninfected individuals; costs and QALYs were discounted at 3% annually. RESULTS: Referral for off-site testing is less efficient (dominated) compared to offering on-site testing with information only. The cost-effectiveness ratio for on-site testing with information is $60,300/QALY in the base case, or $76,300/QALY with 0.1% undiagnosed HIV prevalence. HIV risk-reduction counseling costs $36 per person more without additional benefit. CONCLUSIONS: A strategy of on-site rapid HIV testing offer with information only in substance abuse treatment programs increases life expectancy at a cost-effectiveness ratio <$100,000/QALY. Policymakers and substance abuse treatment leaders should seek funding to implement on-site rapid HIV testing in substance abuse treatment programs for those not recently tested.",2012-01-09751,22971593,Drug Alcohol Depend,Bruce R Schackman,2013,128 / 1-2,,No,22971593,"Bruce R Schackman; Lisa R Metsch; Grant N Colfax; Jared A Leff; Angela Wong; Callie A Scott; Daniel J Feaster; Lauren Gooden; Tim Matheson; Louise F Haynes; A David Paltiel; Rochelle P Walensky; The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial, Drug Alcohol Depend, 2013 Feb 1; 128(1-2):0376-8716",QALY,Not Stated,Not Stated,Not Stated,On-site rapid HIV test with information describing testing procedure but no counseling about risk behaviors vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,60300,United States,2009,72744.11
10236,Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer,"PURPOSE: New evidence is available regarding the utility of the 21-gene recurrence score assay in guiding chemotherapy use for node-negative, estrogen receptor-positive breast cancer. We applied this evidence in a decision-analytic model to re-evaluate the cost-effectiveness of the assay. METHODS: We cross-classified patients by clinicopathologic characteristics from the Adjuvant! risk index and by recurrence score risk group. For non-recurrence score-guided treatment, we assumed patients receiving hormonal therapy alone had low-risk characteristics and patients receiving chemotherapy and hormonal therapy had higher-risk characteristics. For recurrence score-guided treatment, we assigned chemotherapy probabilities conditional on recurrence score risk group and clinicopathologic characteristics. RESULTS: An estimated 40.4% of patients in the recurrence score-guided strategy and 47.3% in the non-recurrence score-guided strategy were expected to receive chemotherapy. The incremental gain in quality-adjusted life-years was 0.16 (95% confidence interval, 0.08-0.28) with the recurrence score-guided strategy. Lifetime medical costs to the health system were $2,692 ($1,546-$3,821) higher with the recurrence score-guided strategy, for an incremental cost-effectiveness ratio of $16,677/quality-adjusted life-year ($7,613-$37,219). From a societal perspective, the incremental cost-effectiveness was $10,788/quality-adjusted life-year ($6,840-$30,265). CONCLUSION: The findings provide supportive evidence for the economic value of the 21-gene recurrence score assay in node-negative, estrogen receptor-positive breast cancer.",2012-01-09756,22975761,Genet Med,Shelby D Reed,2013,15 / 3,,No,22975761,"Shelby D Reed; Michaela A Dinan; Kevin A Schulman; Gary H Lyman; Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer, Genet Med, 2013 Mar; 15(3):1098-3600",QALY,Not Stated,Not Stated,Not Stated,21-gene recurrence score assay in guiding chemotherapy vs. Non-recurrence score-guided treatment with risk classication based on clinicopathologic characteristics,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,16677,United States,2011,19188.27
10237,Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer,"PURPOSE: New evidence is available regarding the utility of the 21-gene recurrence score assay in guiding chemotherapy use for node-negative, estrogen receptor-positive breast cancer. We applied this evidence in a decision-analytic model to re-evaluate the cost-effectiveness of the assay. METHODS: We cross-classified patients by clinicopathologic characteristics from the Adjuvant! risk index and by recurrence score risk group. For non-recurrence score-guided treatment, we assumed patients receiving hormonal therapy alone had low-risk characteristics and patients receiving chemotherapy and hormonal therapy had higher-risk characteristics. For recurrence score-guided treatment, we assigned chemotherapy probabilities conditional on recurrence score risk group and clinicopathologic characteristics. RESULTS: An estimated 40.4% of patients in the recurrence score-guided strategy and 47.3% in the non-recurrence score-guided strategy were expected to receive chemotherapy. The incremental gain in quality-adjusted life-years was 0.16 (95% confidence interval, 0.08-0.28) with the recurrence score-guided strategy. Lifetime medical costs to the health system were $2,692 ($1,546-$3,821) higher with the recurrence score-guided strategy, for an incremental cost-effectiveness ratio of $16,677/quality-adjusted life-year ($7,613-$37,219). From a societal perspective, the incremental cost-effectiveness was $10,788/quality-adjusted life-year ($6,840-$30,265). CONCLUSION: The findings provide supportive evidence for the economic value of the 21-gene recurrence score assay in node-negative, estrogen receptor-positive breast cancer.",2012-01-09756,22975761,Genet Med,Shelby D Reed,2013,15 / 3,,No,22975761,"Shelby D Reed; Michaela A Dinan; Kevin A Schulman; Gary H Lyman; Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer, Genet Med, 2013 Mar; 15(3):1098-3600",QALY,Not Stated,Not Stated,Not Stated,21-gene recurrence score assay in guiding chemotherapy vs. Non-recurrence score-guided treatment with risk classication based on clinicopathologic characteristics,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,10788,United States,2011,12412.49
10238,Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease,"BACKGROUND: Top-down (TD) strategy with frontline infliximab proved to be more effective than the traditional step-up (SU) approach in newly diagnosed luminal moderate-to-severe CD patients. However, the considerable cost of infliximab calls its universal use as frontline treatment into question. The aim of this study is to evaluate the cost-effectiveness of the TD approach using a Markov decision model. METHODS: Four states were modelled, namely step 1, step 2, step 3 and death. The first three steps were in TD infliximab induction plus azathioprine, infliximab rechallenge plus azathioprine and steroids plus azathioprine, and in SU steroid induction, azathioprine plus steroid rechallenge and infliximab plus azathioprine. Each health state lasted 1 month. The time horizon of the model was 5 years. Transition probabilities and quality of life were estimated from a randomised trial. First- and second-order sensitivity analyses were done to test the robustness of the results. RESULTS: At baseline analysis, TD improved quality-adjusted life expectancy from 3.76 to 3.90 quality-adjusted life years (QALYs), that is, 0.14 QALYs, while allowing a saving of euro 773, proving dominant when compared to SU. TD was cost-saving in 66% of the Monte Carlo simulations and cost <euro 20,000/QALY in 84%. At sensitivity analysis the most significant variables were infliximab cost and time horizon: doubling infliximab cost (euro 1,000 per 100 mg vial) resulted in an incremental cost-utility ratio of euro 12,114/QALY. CONCLUSIONS: TD is a cost-effective treatment in newly diagnosed CD patients with luminal moderate-to-severe disease, and sensitivity analysis showed the result to be robust.",2012-01-09757,22975794,Eur J Health Econ,Monia Marchetti,2013,14 / 6,,Yes,22975794,"Monia Marchetti; Nicola L Liberato; Antonio Di Sabatino; Gino R Corazza; Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease, Eur J Health Econ, ; 14(6):1618-7598",QALY,Not Stated,Not Stated,Not Stated,Top-down strategy (TD)- induction treatment of combined immunosupressive therapy with inflixmab (2.5 mg/kg/day) and if symptom exacerbation occurred additional inflixmab infusions and methylprednisone (32 mg/day for 3 weeks followed by 4 mg/week dose tapering) prescribed vs. Step-up strategy (SU)- induction treatment of methylprednisone and if symptom exacerbation or relapse occurred azathiprine and infliximab were added to treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,3.50,3.50,-5521.43,Euro,2010,-8673
10239,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Aerobic training,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,4792,Canada,2008,5438.7
10240,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Resistance training,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,8570,Canada,2008,9726.55
10241,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,37782,Canada,2008,42880.81
10242,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Aerobic program to improve glycemic control vs. Resistance program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,23275,Canada,2008,26416.04
10243,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Aerobic program to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,116793,Canada,2008,132554.61
10244,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Resistance program to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,241466.67,Canada,2008,274053.41
10245,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,36985,Canada,2008,41976.25
10246,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Resistance program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,7929,Canada,2008,8999.05
10247,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Aerobic training,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,3358,Canada,2008,3811.17
10248,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,United States of America,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,45100,Canada,2008,51186.4
10249,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,United States of America,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Resistance program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,8021,Canada,2008,9103.46
10250,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,United States of America,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Aerobic program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,3822,Canada,2008,4337.79
10251,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,36702,Canada,2008,41655.06
10252,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Resistance program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,9003,Canada,2008,10217.99
10253,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Aerobic training,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,3645,Canada,2008,4136.91
10254,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,45211,Canada,2008,51312.38
10255,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Resistance program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,8423,Canada,2008,9559.71
10256,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Aerobic training,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,5770,Canada,2008,6548.68
10257,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,39177,Canada,2008,44464.07
10258,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Resistance program,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,15269,Canada,2008,17329.6
10259,Cost-effectiveness of exercise programs in type 2 diabetes,"A randomized controlled trial has shown that supervised, facility-based exercise training is effective in improving glycemic control in type 2 diabetes. However, these programs are associated with additional costs. This analysis assessed the cost-effectiveness of such programs.Analysis used data from the Diabetes Aerobic and Resistance Exercise (DARE) clinical trial which compared three different exercise programs (resistance, aerobic or a combination of both) of 6 months duration with a control group (no exercise program). Clinical outcomes at 6 months were entered for individual patients into the UKPDS economic model for type 2 diabetes adapted for the Canadian context. From this, expected life-years, quality-adjusted life-years (QALYs) and costs were estimated for all patients within the trial.The combined exercise program was the most expensive ($40,050) followed by the aerobic program ($39,250), the resistance program ($38,300) and no program ($31,075). QALYs were highest for combined (8.94), followed by aerobic (8.77), resistance (8.73) and no program (8.70). The incremental cost per QALY gained for the combined exercise program was $4,792 compared with aerobic alone, $8,570 compared with resistance alone, and $37,872 compared with no program. The combined exercise program remained cost-effective for all scenarios considered within sensitivity analysis.A program providing training in both resistance and aerobic exercise was the most cost-effective of the alternatives compared. Based on previous funding decisions, exercise training for individuals with diabetes can be considered an efficient use of resources.",2012-01-09762,22980698,Int J Technol Assess Health Care,Doug Coyle,2012,28 / 3,228-34,No,22980698,"Doug Coyle; Kathryn Coyle; Glen P Kenny; Normand G Boul?; George A Wells; Michelle Fortier; Robert D Reid; Penny Phillips; Ronald J Sigal; Cost-effectiveness of exercise programs in type 2 diabetes, Int J Technol Assess Health Care, ; 28(3):0266-4623; 228-34",QALY,Not Stated,Not Stated,Not Stated,Combined exercise program of aerobic and resistance training to improve glycemic control vs. Aerobic training,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,5259,Canada,2008,5968.72
10260,Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia,"The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL).We developed a decision-analytic model to assess the costs and benefits of alemtuzumab or conventional therapy based on their effects on quality of life of patients. The main outcome was the incremental cost-effectiveness ratio incorporating costs per additional quality-adjusted life-year (QALY) gained over lifetime. Due to the limited data available, a large number of assumptions had to be made to construct the cost-utility model. One-way, multi-way, and probabilistic sensitivity analyses (PSA) were conducted to explore the impact of these uncertainties. Expected values of perfect information were also calculated for four specific scenarios.Depending on different key assumptions made, the PSA suggested distinct conclusions using a willingness-to-pay threshold of 30,000 GBP per QALY gained. Using this threshold, the probability that alemtuzumab would be cost-effective varies from 0 percent to 53 percent for the four modeled scenarios. Population expected value of perfect information analysis suggests that resolving the parameter uncertainty in the analysis for people with T-PLL in the United Kingdom would have considerable value--up to 5.3 million euro.Alemtuzumab appears more likely to be cost-effective if used earlier in the course of T-PLL and where it replaces the use of multiple alternative therapies. However, cost-effectiveness is highly uncertain and future research is clearly justified. Nevertheless, our analysis demonstrates the feasibility of considering the cost-effectiveness of an agent despite the presence of significant uncertainty to provide appropriate assessment information to policy makers.",2012-01-09763,22980700,Int J Technol Assess Health Care,Lanting Lu,2012,28 / 3,241-8,No,22980700,"Lanting Lu; Jaime Peters; Chris Roome; Ken Stein; Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia, Int J Technol Assess Health Care, ; 28(3):0266-4623; 241-8",QALY,Not Stated,Not Stated,Not Stated,Alemtuzumab (treatment begins 7 months after diagnosis) vs. Conventional therapy (1 line),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,95746,Euro,2012,138784.6
10261,Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia,"The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL).We developed a decision-analytic model to assess the costs and benefits of alemtuzumab or conventional therapy based on their effects on quality of life of patients. The main outcome was the incremental cost-effectiveness ratio incorporating costs per additional quality-adjusted life-year (QALY) gained over lifetime. Due to the limited data available, a large number of assumptions had to be made to construct the cost-utility model. One-way, multi-way, and probabilistic sensitivity analyses (PSA) were conducted to explore the impact of these uncertainties. Expected values of perfect information were also calculated for four specific scenarios.Depending on different key assumptions made, the PSA suggested distinct conclusions using a willingness-to-pay threshold of 30,000 GBP per QALY gained. Using this threshold, the probability that alemtuzumab would be cost-effective varies from 0 percent to 53 percent for the four modeled scenarios. Population expected value of perfect information analysis suggests that resolving the parameter uncertainty in the analysis for people with T-PLL in the United Kingdom would have considerable value--up to 5.3 million euro.Alemtuzumab appears more likely to be cost-effective if used earlier in the course of T-PLL and where it replaces the use of multiple alternative therapies. However, cost-effectiveness is highly uncertain and future research is clearly justified. Nevertheless, our analysis demonstrates the feasibility of considering the cost-effectiveness of an agent despite the presence of significant uncertainty to provide appropriate assessment information to policy makers.",2012-01-09763,22980700,Int J Technol Assess Health Care,Lanting Lu,2012,28 / 3,241-8,No,22980700,"Lanting Lu; Jaime Peters; Chris Roome; Ken Stein; Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia, Int J Technol Assess Health Care, ; 28(3):0266-4623; 241-8",QALY,Not Stated,Not Stated,Not Stated,Alemtuzumab (treatment begins 3 months after diagnosis) vs. Conventional therapy (1 line),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,64793,Euro,2012,93917.98
10262,Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia,"The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL).We developed a decision-analytic model to assess the costs and benefits of alemtuzumab or conventional therapy based on their effects on quality of life of patients. The main outcome was the incremental cost-effectiveness ratio incorporating costs per additional quality-adjusted life-year (QALY) gained over lifetime. Due to the limited data available, a large number of assumptions had to be made to construct the cost-utility model. One-way, multi-way, and probabilistic sensitivity analyses (PSA) were conducted to explore the impact of these uncertainties. Expected values of perfect information were also calculated for four specific scenarios.Depending on different key assumptions made, the PSA suggested distinct conclusions using a willingness-to-pay threshold of 30,000 GBP per QALY gained. Using this threshold, the probability that alemtuzumab would be cost-effective varies from 0 percent to 53 percent for the four modeled scenarios. Population expected value of perfect information analysis suggests that resolving the parameter uncertainty in the analysis for people with T-PLL in the United Kingdom would have considerable value--up to 5.3 million euro.Alemtuzumab appears more likely to be cost-effective if used earlier in the course of T-PLL and where it replaces the use of multiple alternative therapies. However, cost-effectiveness is highly uncertain and future research is clearly justified. Nevertheless, our analysis demonstrates the feasibility of considering the cost-effectiveness of an agent despite the presence of significant uncertainty to provide appropriate assessment information to policy makers.",2012-01-09763,22980700,Int J Technol Assess Health Care,Lanting Lu,2012,28 / 3,241-8,No,22980700,"Lanting Lu; Jaime Peters; Chris Roome; Ken Stein; Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia, Int J Technol Assess Health Care, ; 28(3):0266-4623; 241-8",QALY,Not Stated,Not Stated,Not Stated,Alemtuzumab (treatment begins 7 months after diagnosis) vs. Conventional therapy (3 lines),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,40265,Euro,2012,58364.44
10263,Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia,"The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL).We developed a decision-analytic model to assess the costs and benefits of alemtuzumab or conventional therapy based on their effects on quality of life of patients. The main outcome was the incremental cost-effectiveness ratio incorporating costs per additional quality-adjusted life-year (QALY) gained over lifetime. Due to the limited data available, a large number of assumptions had to be made to construct the cost-utility model. One-way, multi-way, and probabilistic sensitivity analyses (PSA) were conducted to explore the impact of these uncertainties. Expected values of perfect information were also calculated for four specific scenarios.Depending on different key assumptions made, the PSA suggested distinct conclusions using a willingness-to-pay threshold of 30,000 GBP per QALY gained. Using this threshold, the probability that alemtuzumab would be cost-effective varies from 0 percent to 53 percent for the four modeled scenarios. Population expected value of perfect information analysis suggests that resolving the parameter uncertainty in the analysis for people with T-PLL in the United Kingdom would have considerable value--up to 5.3 million euro.Alemtuzumab appears more likely to be cost-effective if used earlier in the course of T-PLL and where it replaces the use of multiple alternative therapies. However, cost-effectiveness is highly uncertain and future research is clearly justified. Nevertheless, our analysis demonstrates the feasibility of considering the cost-effectiveness of an agent despite the presence of significant uncertainty to provide appropriate assessment information to policy makers.",2012-01-09763,22980700,Int J Technol Assess Health Care,Lanting Lu,2012,28 / 3,241-8,No,22980700,"Lanting Lu; Jaime Peters; Chris Roome; Ken Stein; Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia, Int J Technol Assess Health Care, ; 28(3):0266-4623; 241-8",QALY,Not Stated,Not Stated,Not Stated,Alemtuzumab (treatment begins 3 months after diagnosis) vs. onventional therapy (3 lines),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,34163,Euro,2012,49519.55
10264,Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension,"The purpose of this study was to assess cost-effectiveness and long-term clinical benefits of renal denervation in resistant hypertensive patients.Resistant hypertension affects 12% of hypertensive persons. In the Symplicity HTN-2 randomized controlled trial, catheter-based renal denervation (RDN) lowered systolic blood pressure by 32 ? 23 mm Hg from 178 ? 18 mm Hg at baseline.A state-transition model was used to predict the effect of RDN and standard of care on 10-year and lifetime probabilities of stroke, myocardial infarction, all coronary heart disease, heart failure, end-stage renal disease, and median survival. We adopted a societal perspective and estimated an incremental cost-effectiveness ratio in U.S. dollars per quality-adjusted life-year, both discounted at 3% per year. Robustness and uncertainty were evaluated using deterministic and probabilistic sensitivity analyses.Renal denervation substantially reduced event probabilities (10-year/lifetime relative risks: stroke 0.70/0.83; myocardial infarction 0.68/0.85; all coronary heart disease 0.78/0.90; heart failure 0.79/0.92; end-stage renal disease 0.72/0.81). Median survival was 18.4 years for RDN versus 17.1 years for standard of care. The discounted lifetime incremental cost-effectiveness ratio was $3,071 per quality-adjusted life-year. Findings were relatively insensitive to variations in input parameters except for systolic blood pressure reduction, baseline systolic blood pressure, and effect duration. The 95% credible interval for incremental cost-effectiveness ratio was cost-saving to $31,460 per quality-adjusted life-year.The model suggests that catheter-based renal denervation, over a wide range of assumptions, is a cost-effective strategy for resistant hypertension that might result in lower cardiovascular morbidity and mortality.",2012-01-09764,22981547,J Am Coll Cardiol,Benjamin P Geisler,2012,60 / 14,1271-7,No,22981547,"Benjamin P Geisler; Brent M Egan; Joshua T Cohen; Abigail M Garner; Ronald L Akehurst; Murray D Esler; Jan B Pietzsch; Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension, J Am Coll Cardiol, Oct/2/2012; 60(14):0735-1097; 1271-7",QALY,Not Stated,Not Stated,Not Stated,Catheter-based renal denervation (RDN) + standard of care vs. Standard of care (3 or more hypertensive medications),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,1830,United States,2010,2172.03
10265,Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension,"The purpose of this study was to assess cost-effectiveness and long-term clinical benefits of renal denervation in resistant hypertensive patients.Resistant hypertension affects 12% of hypertensive persons. In the Symplicity HTN-2 randomized controlled trial, catheter-based renal denervation (RDN) lowered systolic blood pressure by 32 ? 23 mm Hg from 178 ? 18 mm Hg at baseline.A state-transition model was used to predict the effect of RDN and standard of care on 10-year and lifetime probabilities of stroke, myocardial infarction, all coronary heart disease, heart failure, end-stage renal disease, and median survival. We adopted a societal perspective and estimated an incremental cost-effectiveness ratio in U.S. dollars per quality-adjusted life-year, both discounted at 3% per year. Robustness and uncertainty were evaluated using deterministic and probabilistic sensitivity analyses.Renal denervation substantially reduced event probabilities (10-year/lifetime relative risks: stroke 0.70/0.83; myocardial infarction 0.68/0.85; all coronary heart disease 0.78/0.90; heart failure 0.79/0.92; end-stage renal disease 0.72/0.81). Median survival was 18.4 years for RDN versus 17.1 years for standard of care. The discounted lifetime incremental cost-effectiveness ratio was $3,071 per quality-adjusted life-year. Findings were relatively insensitive to variations in input parameters except for systolic blood pressure reduction, baseline systolic blood pressure, and effect duration. The 95% credible interval for incremental cost-effectiveness ratio was cost-saving to $31,460 per quality-adjusted life-year.The model suggests that catheter-based renal denervation, over a wide range of assumptions, is a cost-effective strategy for resistant hypertension that might result in lower cardiovascular morbidity and mortality.",2012-01-09764,22981547,J Am Coll Cardiol,Benjamin P Geisler,2012,60 / 14,1271-7,No,22981547,"Benjamin P Geisler; Brent M Egan; Joshua T Cohen; Abigail M Garner; Ronald L Akehurst; Murray D Esler; Jan B Pietzsch; Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension, J Am Coll Cardiol, Oct/2/2012; 60(14):0735-1097; 1271-7",QALY,Not Stated,Not Stated,Not Stated,Catheter-based renal denervation (RDN) + standard of care vs. Standard of care (3 or more hypertensive medications),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,2732,United States,2010,3242.61
10266,Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations,"Accelerated partial breast radiotherapy (RT) strategies (3-D conformal external-beam RT (3-D CRT) and brachytherapy with balloon catheter) reduce time and transportation burdens of whole breast RT for breast cancer. Long-term clinical trial evidence is unavailable for accelerated modalities, but uncertainty might be acceptable for patients likely to receive suboptimal whole breast RT. The objective of this study is to assess the cost effectiveness of accelerated partial breast RT compared to on-time and delayed whole breast RT. The design used in this study is decision analytic Markov model. The data sources are published literature; and national/federal sources. The target population of this study is a hypothetical cohort of 60?years old women previously treated with breast-conserving surgery for node-negative, estrogen receptor-positive breast cancer with tumors <1?cm. The time horizon is 15?years, and the perspective is societal. The interventions are whole breast RT, 3-D CRT, and brachytherapy breast irradiation. The outcome measures are costs (2008 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. The base-case results were: 3-D CRT was the preferred strategy, costing on average $10,800 and yielding 11.21 QALYs. On-time whole breast RT costs $368,000/QALY compared to 3-D CRT, above the $100,000/QALY WTP threshold. 3-D CRT was also preferred over delayed whole breast RT. Brachytherapy was never preferred. Sensitivity analysis indicated that the results were sensitive to the rate of recurrence outside the initial tumor quadrant (""elsewhere failure"") in one-way analysis. Probabilistic sensitivity analysis indicated that results were sensitive to parameter uncertainty, and that the elsewhere-failure rate and treatment preferences may drive results. The limitation of this study is that efficacy estimates are derived from studies that may not fully represent the population modeled. As a conclusion, 3-D CRT was preferred to whole breast RT and for women likely to delay RT, indicating that 3-D CRT could be targeted more efficiently before randomized trial evidence.",2012-01-09767,22983837,Breast Cancer Res Treat,Heather Taffet Gold,2012,136 / 1,221-9,No,22983837,"Heather Taffet Gold; Mary Katherine Hayes; Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations, Breast Cancer Res Treat, ; 136(1):0167-6806; 221-9",QALY,Not Stated,Not Stated,Not Stated,Accelerated partial breast radiotherapy aka 3-dimensional conformal radiotherapy (3DCRT) vs. On-time whole breast radiotherapy (WBRT),Not Stated,Not Stated,61 Years,Female,Full,15 Years,3.00,3.00,367740,United States,2008,442052.16
10267,Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations,"Accelerated partial breast radiotherapy (RT) strategies (3-D conformal external-beam RT (3-D CRT) and brachytherapy with balloon catheter) reduce time and transportation burdens of whole breast RT for breast cancer. Long-term clinical trial evidence is unavailable for accelerated modalities, but uncertainty might be acceptable for patients likely to receive suboptimal whole breast RT. The objective of this study is to assess the cost effectiveness of accelerated partial breast RT compared to on-time and delayed whole breast RT. The design used in this study is decision analytic Markov model. The data sources are published literature; and national/federal sources. The target population of this study is a hypothetical cohort of 60?years old women previously treated with breast-conserving surgery for node-negative, estrogen receptor-positive breast cancer with tumors <1?cm. The time horizon is 15?years, and the perspective is societal. The interventions are whole breast RT, 3-D CRT, and brachytherapy breast irradiation. The outcome measures are costs (2008 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. The base-case results were: 3-D CRT was the preferred strategy, costing on average $10,800 and yielding 11.21 QALYs. On-time whole breast RT costs $368,000/QALY compared to 3-D CRT, above the $100,000/QALY WTP threshold. 3-D CRT was also preferred over delayed whole breast RT. Brachytherapy was never preferred. Sensitivity analysis indicated that the results were sensitive to the rate of recurrence outside the initial tumor quadrant (""elsewhere failure"") in one-way analysis. Probabilistic sensitivity analysis indicated that results were sensitive to parameter uncertainty, and that the elsewhere-failure rate and treatment preferences may drive results. The limitation of this study is that efficacy estimates are derived from studies that may not fully represent the population modeled. As a conclusion, 3-D CRT was preferred to whole breast RT and for women likely to delay RT, indicating that 3-D CRT could be targeted more efficiently before randomized trial evidence.",2012-01-09767,22983837,Breast Cancer Res Treat,Heather Taffet Gold,2012,136 / 1,221-9,No,22983837,"Heather Taffet Gold; Mary Katherine Hayes; Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations, Breast Cancer Res Treat, ; 136(1):0167-6806; 221-9",QALY,Not Stated,Not Stated,Not Stated,On-time whole breast radiotherapy (WBRT) vs. Brachytherapy,Not Stated,Not Stated,61 Years,Female,Full,15 Years,3.00,3.00,-11691999,United States,2008,-14054694.79
10268,Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations,"Accelerated partial breast radiotherapy (RT) strategies (3-D conformal external-beam RT (3-D CRT) and brachytherapy with balloon catheter) reduce time and transportation burdens of whole breast RT for breast cancer. Long-term clinical trial evidence is unavailable for accelerated modalities, but uncertainty might be acceptable for patients likely to receive suboptimal whole breast RT. The objective of this study is to assess the cost effectiveness of accelerated partial breast RT compared to on-time and delayed whole breast RT. The design used in this study is decision analytic Markov model. The data sources are published literature; and national/federal sources. The target population of this study is a hypothetical cohort of 60?years old women previously treated with breast-conserving surgery for node-negative, estrogen receptor-positive breast cancer with tumors <1?cm. The time horizon is 15?years, and the perspective is societal. The interventions are whole breast RT, 3-D CRT, and brachytherapy breast irradiation. The outcome measures are costs (2008 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. The base-case results were: 3-D CRT was the preferred strategy, costing on average $10,800 and yielding 11.21 QALYs. On-time whole breast RT costs $368,000/QALY compared to 3-D CRT, above the $100,000/QALY WTP threshold. 3-D CRT was also preferred over delayed whole breast RT. Brachytherapy was never preferred. Sensitivity analysis indicated that the results were sensitive to the rate of recurrence outside the initial tumor quadrant (""elsewhere failure"") in one-way analysis. Probabilistic sensitivity analysis indicated that results were sensitive to parameter uncertainty, and that the elsewhere-failure rate and treatment preferences may drive results. The limitation of this study is that efficacy estimates are derived from studies that may not fully represent the population modeled. As a conclusion, 3-D CRT was preferred to whole breast RT and for women likely to delay RT, indicating that 3-D CRT could be targeted more efficiently before randomized trial evidence.",2012-01-09767,22983837,Breast Cancer Res Treat,Heather Taffet Gold,2012,136 / 1,221-9,No,22983837,"Heather Taffet Gold; Mary Katherine Hayes; Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations, Breast Cancer Res Treat, ; 136(1):0167-6806; 221-9",QALY,Not Stated,Not Stated,Not Stated,Accelerated partial breast radiotherapy aka 3-dimensional conformal radiotherapy (3DCRT) vs. 8+ week-delay whole breast radiotherapy (WBRT),Not Stated,Not Stated,61 Years,Female,Full,15 Years,3.00,3.00,Not Stated,United States,2008,Not Stated
10269,Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations,"Accelerated partial breast radiotherapy (RT) strategies (3-D conformal external-beam RT (3-D CRT) and brachytherapy with balloon catheter) reduce time and transportation burdens of whole breast RT for breast cancer. Long-term clinical trial evidence is unavailable for accelerated modalities, but uncertainty might be acceptable for patients likely to receive suboptimal whole breast RT. The objective of this study is to assess the cost effectiveness of accelerated partial breast RT compared to on-time and delayed whole breast RT. The design used in this study is decision analytic Markov model. The data sources are published literature; and national/federal sources. The target population of this study is a hypothetical cohort of 60?years old women previously treated with breast-conserving surgery for node-negative, estrogen receptor-positive breast cancer with tumors <1?cm. The time horizon is 15?years, and the perspective is societal. The interventions are whole breast RT, 3-D CRT, and brachytherapy breast irradiation. The outcome measures are costs (2008 US$), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. The base-case results were: 3-D CRT was the preferred strategy, costing on average $10,800 and yielding 11.21 QALYs. On-time whole breast RT costs $368,000/QALY compared to 3-D CRT, above the $100,000/QALY WTP threshold. 3-D CRT was also preferred over delayed whole breast RT. Brachytherapy was never preferred. Sensitivity analysis indicated that the results were sensitive to the rate of recurrence outside the initial tumor quadrant (""elsewhere failure"") in one-way analysis. Probabilistic sensitivity analysis indicated that results were sensitive to parameter uncertainty, and that the elsewhere-failure rate and treatment preferences may drive results. The limitation of this study is that efficacy estimates are derived from studies that may not fully represent the population modeled. As a conclusion, 3-D CRT was preferred to whole breast RT and for women likely to delay RT, indicating that 3-D CRT could be targeted more efficiently before randomized trial evidence.",2012-01-09767,22983837,Breast Cancer Res Treat,Heather Taffet Gold,2012,136 / 1,221-9,No,22983837,"Heather Taffet Gold; Mary Katherine Hayes; Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations, Breast Cancer Res Treat, ; 136(1):0167-6806; 221-9",QALY,Not Stated,Not Stated,Not Stated,Accelerated partial breast radiotherapy aka 3-dimensional conformal radiotherapy (3DCRT) vs. 12+ week-delay whole breast radiotherapy (WBRT),Not Stated,Not Stated,61 Years,Female,Full,15 Years,3.00,3.00,-988999.94,United States,2008,-1188855.07
10270,Is surgery for cervical spondylotic myelopathy cost-effective? A cost-utility analysis based on data from the AOSpine North America prospective CSM study,"Surgical intervention for appropriately selected patients with cervical spondylotic myelopathy (CSM) has demonstrated favorable outcomes. This study evaluates the cost-effectiveness of this type of surgery in terms of cost per quality-adjusted life year (QALY) gained.As part of a larger prospective multicenter study, the direct costs of medical treatment for 70 patients undergoing surgery for CSM at a single institution in Canada were retrospectively obtained from the hospital expenses database and physician reimbursement data. Utilities were estimated on the entire sample of 278 subjects enrolled in the multicenter study using SF-6D-derived utilities from 12- and 24-month SF-36v2 follow-up information. Costs were analyzed from the payer perspective. A 10-year horizon with 3% discounting was applied to health-utilities estimates. Sensitivity analysis was performed by varying utility gain by 20%.The SF-6D utility gain was 0.0734 (95% CI 0.0557-0.0912, p < 0.01) at 12 months and remained unchanged at 24 months. The 10-year discounted QALY gain was 0.64. Direct costs of medical treatment were estimated at an average of CaD $21,066. The estimated cost-utility ratio was CaD $32,916 per QALY gained. The sensitivity analysis showed a range of CaD $27,326-$40,988 per QALY gained. These estimates are within the limits for medical procedures that have an acceptable cost-utility ratio.Surgical treatment for CSM is associated with significant improvement in health utilities as measured by the SF-6D. The direct cost of medical treatment per QALY gained places this form of treatment within the category deemed by payers to be cost-effective.",2012-01-09768,22985375,J Neurosurg Spine,Michael G Fehlings,2012,17 / 1Suppl,89-93,No,22985375,"Michael G Fehlings; Neilank K Jha; Stephanie M Hewson; Eric M Massicotte; Branko Kopjar; Sukhvinder Kalsi-Ryan; Is surgery for cervical spondylotic myelopathy cost-effective? A cost-utility analysis based on data from the AOSpine North America prospective CSM study, J Neurosurg Spine, ; 17(1Suppl):1547-5654; 89-93",QALY,Canada,Not Stated,Not Stated,Surgery vs. Medical management,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,Not Stated,3.00,32916,Canada,2008,37358.12
10271,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,First-line biological treatment with TNF-inhibitor combination therapy (+DMARD methotrexate) vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,54066,Euro,2011,86566.48
10272,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,First-line biological treatment with TNF-inhibitor monotherapy vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,83474,Euro,2011,133652.39
10273,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,First-line biological treatment with etanercept combination therapy (+DMARD methotrexate) vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,49879,Euro,2011,79862.56
10274,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,First-line biological treatment with etanercept monotherapy vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,64902,Euro,2011,103916.28
10275,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,Second-line biological treatment with TNF-inhibitor combination therapy (+DMARD methotrexate) vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,79891,Euro,2011,127915.55
10276,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,Second-line biological treatment with TNF-inhibitor monotherapy vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,120091,Euro,2011,192280.82
10277,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,Second-line biological treatment with etanercept combination therapy (+DMARD methotrexate) vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,70781,Euro,2011,113329.3
10278,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,Second-line biological treatment with etanercept monotherapy vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,84151,Euro,2011,134736.35
10279,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,First-line biological treatment with TNF-inhibitor combination therapy (+DMARD methotrexate) vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,71781,Euro,2011,114930.42
10280,The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice,"OBJECTIVE: The objective was to estimate the cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, both as a first and second biological treatment, with or without the combination of conventional DMARDs. Further sub-group analysis of etanercept treatment was performed. METHODS AND MATERIALS: Patient level data were obtained from three regions of the Swedish Rheumatology Registers. The dataset contained 2,558 patients who had started TNF-inhibitor treatment, 1,049 with etanercept as their first biological treatment. A total of 819 patients had switched to a second TNF-inhibitor, of which 425 to etanercept. A Markov cohort model was used in which health states of disease severity were classified according to HAQ and DAS28. Disease progression and discontinuation rates of TNF-inhibitors were based on the registry and for the comparator on published literature. Mortality, costs and utilities were based on Swedish data. The main analysis had a societal perspective over 20 years and efficacy was measured in quality-adjusted life-years (QALYs). RESULTS: TNF-inhibitor treatment was associated with an increase in QALYs and an incremental cost compared to no biological treatment. The cost per QALY gained with the three TNF-inhibitors ranged from euro 50,000 to euro 120,000, with lower estimates for TNF-inhibitors used in combination with MTX and as a first biologic. At a progression of 0.045 for the comparator, most values remain within the accepted range for cost-effectiveness. CONCLUSIONS: These results demonstrate that the cost per QALY for TNF-inhibitors was higher than in previous assessments based on registry data and that the results were sensitive to the HAQ progression of the comparator.",2012-01-09776,22990378,Eur J Health Econ,Ingrid Lekander,2013,14 / 6,,Yes,22990378,"Ingrid Lekander; Fredrik Borgstrom; Jorgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt; The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice, Eur J Health Econ, ; 14(6):1618-7598",QALY,Sweden,Not Stated,Not Stated,First-line biological treatment with TNF-inhibitor monotherapy vs. No biological treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,20 Years,3.00,3.00,102064,Euro,2011,163417.32
10281,Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation,"To compare the cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in patients with atrial fibrillation (AF).Using standard methods, we created a Markov decision model based on the estimated cost of apixaban and data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial and other trials of warfarin therapy for AF. We quantified the cost and quality-adjusted life expectancy resulting from apixaban 5 mg twice daily compared with those from warfarin therapy targeted to an international normalized ratio of 2-3. Our base case population was a cohort of 70-year-old patients with no contraindication to anticoagulation and a history of stroke or TIA from nonvalvular AF.Warfarin therapy resulted in a quality-adjusted life expectancy of 3.91 years at a cost of $378,500. In comparison, treatment with apixaban led to a quality-adjusted life expectancy of 4.19 years at a cost of $381,700. Therefore, apixaban provided a gain of 0.28 quality-adjusted life-years (QALYs) at an additional cost of $3,200, resulting in an incremental cost-effectiveness ratio of $11,400 per QALY. Our findings were robust in univariate sensitivity analyses varying model inputs across plausible ranges. In Monte Carlo analysis, apixaban was cost-effective in 62% of simulations using a threshold of $50,000 per QALY and 81% of simulations using a threshold of $100,000 per QALY.Apixaban appears to be cost-effective relative to warfarin for secondary stroke prevention in patients with AF, assuming that it is introduced at a price similar to that of dabigatran.",2012-01-09779,22993279,Neurology,Hooman Kamel,2012,79 / 14,1428-34,No,22993279,"Hooman Kamel; J Donald Easton; S Claiborne Johnston; Anthony S Kim; Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation, Neurology, Oct/2/2012; 79(14):1526-632X; 1428-34",QALY,Not Stated,Not Stated,Not Stated,Apixaban (5 mg twice daily) vs. Adjusted-dose warfarin with goal of international normalized ratio (INR) of 2-3,Not Stated,70 Years,70 Years,"Female, Male",Full,20 Years,3.00,3.00,11400,United States,2010,13530.68
10282,Shortened peginterferon and ribavirin treatment for chronic hepatitis C,"Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen. Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK. Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration. Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.",2012-01-09783,22995040,Int J Technol Assess Health Care,Debbie Hartwell,2012,28 / 4,398-406,No,22995040,"Debbie Hartwell; Jeremy Jones; Louise Baxter; Jonathan Shepherd; Shortened peginterferon and ribavirin treatment for chronic hepatitis C, Int J Technol Assess Health Care, ; 28(4):0266-4623; 398-406",QALY,Not Stated,Not Stated,Not Stated,Peginterferon alpha-2a and ribavirin combination therapy for 24 weeks vs. Peginterferon alpha-2a and ribavirin combination therapy for 48 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,34510,United Kingdom,2007,86239.1
10283,Shortened peginterferon and ribavirin treatment for chronic hepatitis C,"Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen. Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK. Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration. Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.",2012-01-09783,22995040,Int J Technol Assess Health Care,Debbie Hartwell,2012,28 / 4,398-406,No,22995040,"Debbie Hartwell; Jeremy Jones; Louise Baxter; Jonathan Shepherd; Shortened peginterferon and ribavirin treatment for chronic hepatitis C, Int J Technol Assess Health Care, ; 28(4):0266-4623; 398-406",QALY,Not Stated,Not Stated,Not Stated,Peginterferon alpha-2a and ribavirin combination therapy for 24 weeks vs. Peginterferon alpha-2a and ribavirin combination therapy for 48 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,64880,United Kingdom,2007,162132.51
10284,Shortened peginterferon and ribavirin treatment for chronic hepatitis C,"Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen. Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK. Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration. Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.",2012-01-09783,22995040,Int J Technol Assess Health Care,Debbie Hartwell,2012,28 / 4,398-406,No,22995040,"Debbie Hartwell; Jeremy Jones; Louise Baxter; Jonathan Shepherd; Shortened peginterferon and ribavirin treatment for chronic hepatitis C, Int J Technol Assess Health Care, ; 28(4):0266-4623; 398-406",QALY,Not Stated,Not Stated,Not Stated,Peginterferon alpha-2a and ribavirin combination therapy for 16 weeks vs. Peginterferon alpha-2a and ribavirin combination therapy for 24 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,-13678.26,United Kingdom,2007,-34181.42
10285,Shortened peginterferon and ribavirin treatment for chronic hepatitis C,"Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen. Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK. Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration. Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.",2012-01-09783,22995040,Int J Technol Assess Health Care,Debbie Hartwell,2012,28 / 4,398-406,No,22995040,"Debbie Hartwell; Jeremy Jones; Louise Baxter; Jonathan Shepherd; Shortened peginterferon and ribavirin treatment for chronic hepatitis C, Int J Technol Assess Health Care, ; 28(4):0266-4623; 398-406",QALY,Not Stated,Not Stated,Not Stated,Peginterferon alpha-2a and ribavirin combination therapy for 16 weeks vs. Peginterferon alpha-2a and ribavirin combination therapy for 24 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,-26337.5,United Kingdom,2007,-65816.35
10286,Shortened peginterferon and ribavirin treatment for chronic hepatitis C,"Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen. Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus standard treatment in the UK. Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent) (24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment. This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than standard treatment duration. Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.",2012-01-09783,22995040,Int J Technol Assess Health Care,Debbie Hartwell,2012,28 / 4,398-406,No,22995040,"Debbie Hartwell; Jeremy Jones; Louise Baxter; Jonathan Shepherd; Shortened peginterferon and ribavirin treatment for chronic hepatitis C, Int J Technol Assess Health Care, ; 28(4):0266-4623; 398-406",QALY,Not Stated,Not Stated,Not Stated,Peginterferon alpha-2b and ribavirin combination therapy for 24 weeks vs. Peginterferon alpha-2b and ribavirin combination therapy for 48 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,-31020.69,United Kingdom,2007,-77519.46
10287,An economic model of school-based behavioral interventions to prevent sexually transmitted infections,"Objectives: Reducing sexually transmitted infections (STI) and teenage pregnancy through effective health education is a high priority for health policy. Behavioral interventions which teach skills to practice safer sex may reduce the incidence of STIs. We evaluated the cost-effectiveness of school-based behavioral interventions in young people. Methods: We developed an economic model to estimate the total number of STI cases averted, consequent gain in health related quality of life (HRQoL) and savings in medical costs, based on changes in sexual behavior. The parameters for the model were derived from a systematic literature search on the intervention effectiveness, epidemiology of STIs, sexual behavior and lifestyles, HRQoL and health service costs. Results: The costs of providing teacher-led and peer-led behavioral interventions were ?5.16 and ?18 per pupil, respectively. For a cohort of 1000 boys and 1000 girls aged 15 years, the model estimated that the behavioral interventions would avert two STI cases and save 0.35 Quality Adjusted Life Years (QALYs). Compared to standard education, the incremental cost-effectiveness of the teacher-led and peer-led interventions was ?24,268 and ?96,938 per QALY gained, respectively. Conclusions: School-based behavioral interventions which provide information and teach young people sexual health skills can bring about improvements in knowledge and increased self-efficacy, though these may be limited in terms of impact on sexual behavior. There was uncertainty around the results due to the limited effect of the intervention on behavioral outcomes and paucity of data for other input parameters.",2012-01-09784,22995075,Int J Technol Assess Health Care,Keith Cooper,2012,28 / 4,407-14,No,22995075,"Keith Cooper; Jonathan Shepherd; Jo Picot; Jeremy Jones; Josephine Kavanagh; Angela Harden; Elaine Barnett-Page; Andrew Clegg; Debbie Hartwell; Geoff Frampton; Alison Price; An economic model of school-based behavioral interventions to prevent sexually transmitted infections, Int J Technol Assess Health Care, ; 28(4):0266-4623; 407-14",QALY,Not Stated,Not Stated,Not Stated,"Teacher-led intervention (20 sessions over 2-year period, involved information leaflets on sexual health, skill development) vs. Standard sexual health education (provided in British schools as part of general curriculum)",Not Stated,15 Years,15 Years,"Female, Male",Full,Years,Not Stated,Not Stated,24268,Euro,2010,38119.92
10288,An economic model of school-based behavioral interventions to prevent sexually transmitted infections,"Objectives: Reducing sexually transmitted infections (STI) and teenage pregnancy through effective health education is a high priority for health policy. Behavioral interventions which teach skills to practice safer sex may reduce the incidence of STIs. We evaluated the cost-effectiveness of school-based behavioral interventions in young people. Methods: We developed an economic model to estimate the total number of STI cases averted, consequent gain in health related quality of life (HRQoL) and savings in medical costs, based on changes in sexual behavior. The parameters for the model were derived from a systematic literature search on the intervention effectiveness, epidemiology of STIs, sexual behavior and lifestyles, HRQoL and health service costs. Results: The costs of providing teacher-led and peer-led behavioral interventions were ?5.16 and ?18 per pupil, respectively. For a cohort of 1000 boys and 1000 girls aged 15 years, the model estimated that the behavioral interventions would avert two STI cases and save 0.35 Quality Adjusted Life Years (QALYs). Compared to standard education, the incremental cost-effectiveness of the teacher-led and peer-led interventions was ?24,268 and ?96,938 per QALY gained, respectively. Conclusions: School-based behavioral interventions which provide information and teach young people sexual health skills can bring about improvements in knowledge and increased self-efficacy, though these may be limited in terms of impact on sexual behavior. There was uncertainty around the results due to the limited effect of the intervention on behavioral outcomes and paucity of data for other input parameters.",2012-01-09784,22995075,Int J Technol Assess Health Care,Keith Cooper,2012,28 / 4,407-14,No,22995075,"Keith Cooper; Jonathan Shepherd; Jo Picot; Jeremy Jones; Josephine Kavanagh; Angela Harden; Elaine Barnett-Page; Andrew Clegg; Debbie Hartwell; Geoff Frampton; Alison Price; An economic model of school-based behavioral interventions to prevent sexually transmitted infections, Int J Technol Assess Health Care, ; 28(4):0266-4623; 407-14",QALY,Not Stated,Not Stated,Not Stated,Peer-led intervention (3 one-hour sessions led by peer educator lasting over one school term) vs. Standard sexual health education (provided in British schools as part of general curriculum),Not Stated,15 Years,15 Years,"Female, Male",Full,Years,Not Stated,Not Stated,96938,Euro,2010,152269.19
10289,An economic model of school-based behavioral interventions to prevent sexually transmitted infections,"Objectives: Reducing sexually transmitted infections (STI) and teenage pregnancy through effective health education is a high priority for health policy. Behavioral interventions which teach skills to practice safer sex may reduce the incidence of STIs. We evaluated the cost-effectiveness of school-based behavioral interventions in young people. Methods: We developed an economic model to estimate the total number of STI cases averted, consequent gain in health related quality of life (HRQoL) and savings in medical costs, based on changes in sexual behavior. The parameters for the model were derived from a systematic literature search on the intervention effectiveness, epidemiology of STIs, sexual behavior and lifestyles, HRQoL and health service costs. Results: The costs of providing teacher-led and peer-led behavioral interventions were ?5.16 and ?18 per pupil, respectively. For a cohort of 1000 boys and 1000 girls aged 15 years, the model estimated that the behavioral interventions would avert two STI cases and save 0.35 Quality Adjusted Life Years (QALYs). Compared to standard education, the incremental cost-effectiveness of the teacher-led and peer-led interventions was ?24,268 and ?96,938 per QALY gained, respectively. Conclusions: School-based behavioral interventions which provide information and teach young people sexual health skills can bring about improvements in knowledge and increased self-efficacy, though these may be limited in terms of impact on sexual behavior. There was uncertainty around the results due to the limited effect of the intervention on behavioral outcomes and paucity of data for other input parameters.",2012-01-09784,22995075,Int J Technol Assess Health Care,Keith Cooper,2012,28 / 4,407-14,No,22995075,"Keith Cooper; Jonathan Shepherd; Jo Picot; Jeremy Jones; Josephine Kavanagh; Angela Harden; Elaine Barnett-Page; Andrew Clegg; Debbie Hartwell; Geoff Frampton; Alison Price; An economic model of school-based behavioral interventions to prevent sexually transmitted infections, Int J Technol Assess Health Care, ; 28(4):0266-4623; 407-14",QALY,Not Stated,Not Stated,Not Stated,"Teacher-led intervention (20 sessions over 2-year period, involved information leaflets on sexual health, skill development) vs. Standard sexual health education (provided in British schools as part of general curriculum)",Not Stated,19 Years,16 Years,"Female, Male",Full,Years,Not Stated,Not Stated,13994,Euro,2010,21981.63
10290,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,"Mailed education (biannual mailings describing the reason to use secondary prevention medications following MI, risk of not taking them, information on adverse effects, and the importance of refilling prescriptions) to improve medication adherence vs. Usual care (no adherence intervention)",Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,-34239.13,United States,2010,-40638.47
10291,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Mailed education + disease management to improve medication adherence vs. Usual care (no adherence intervention),Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,74600,United States,2010,88542.85
10292,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,"Disease management (received ongoing care from a specially trained pharmacist, including medication review, assessment of patients knowledge and skills, electronic drug monitoring, and communications with patients primary care physicians) to improve medication adherence vs. Usual care (no adherence intervention)",Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,69200,United States,2010,82133.59
10293,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Polypill use (single pill containing all four-drug components of combination pharmacotherapy) to improve medication adherence vs. Usual care (no adherence intervention),Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,133000,United States,2010,157857.9
10294,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Polypill use + mailed education to improve medication adherence vs. Usual care (no adherence intervention),Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,113000,United States,2010,134119.87
10295,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Polypill use + disease management to improve medication adherence vs. Usual care (no adherence intervention),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,142900,United States,2010,169608.23
10296,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Disease management to improve medication adherence vs. Mailed education,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,130800,United States,2010,155246.72
10297,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Polypill use + mailed education to improve medication adherence vs. Mailed education,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,193000,United States,2010,229072
10298,Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction,"To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.Cost-effectiveness analysis.We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.Model inputs were extracted from published literature.Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.",2012-01-09787,22998129,Health Serv Res,Kouta Ito,2012,47 / 6,2097-117,No,22998129,"Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry; Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction, Health Serv Res, ; 47(6):0017-9124; 2097-117",QALY,Not Stated,Not Stated,Not Stated,Polypill use + disease management to improve medication adherence vs. Polypill use,Not Stated,65 Years,65 Years,"Female, Male",Full,Lifetime,3.00,3.00,259500,United States,2010,308000.95
10299,Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens,"The diagnostic algorithm for most cancers includes the assessment of a tissue specimen by a surgical pathologist, but if specimen provenance is uncertain, the diagnostic and therapeutic process carries significant risk to the patient. Over the last decade, short tandem repeat (STR) analysis has emerged as a DNA-based method with clinical applicability for specimen identity testing (also known as specimen provenance testing). Although the clinical utility of identity testing using STR-based analysis has been demonstrated in many studies, its economic value has not been established.We developed a decision-analytic model of the application of STR-based provenance testing of transrectal prostate biopsy specimens obtained as part of routine clinical care to rule out the presence of adenocarcinoma of the prostate, as compared with no STR-based testing. Using parameter values drawn from the published literature, the cost-effectiveness of STR-based testing was quantified by calculating the incremental cost-effectiveness ratio per quality-adjusted life-year gained.In comparison to the current standard practice of no identity testing, identity testing by STR-based analysis has an incremental cost-effectiveness ratio of $65,570 per quality-adjusted life-year gained at a testing cost of $618 per person. At a cost of $515 per person, identity testing would meet the conservative standard of $50,000 per quality-adjusted life-year. At a test cost of $290 per person, identity testing would be cost saving.Given the rapidly declining pricing of STR-based identity testing, it is likely that testing to confirm the identity of positive prostate biopsy samples will be a cost-effective method for preventing treatment errors stemming from misidentification. Studies to formally establish the frequency of specimen provenance errors in routine clinical practice would therefore seem justified.",2012-01-09788,22999136,Value Health,John D Pfeifer,2012,15 / 6,860-7,Yes,22999136,"John D Pfeifer; Michael N Singleton; Martin H Gregory; Dennis L Lambert; Steven M Kymes; Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens, Value Health, ; 15(6):1098-3015; 860-7",QALY,Not Stated,Not Stated,Not Stated,Short-tandem repeat-based provenance testing of transrectal prostate biopsy specimens to rule out the presence of adenocarcinoma of the prostate vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,65570,United States,2009,79101.68
10300,Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response,"Shortened courses of treatment with pegylated interferon alfa and ribavirin for patients with hepatitis C virus infection who experience rapid virologic response can be effective in appropriately selected patients. The cost-effectiveness of truncated therapy is not known.To assess the cost-effectiveness of response-guided therapy versus standard-duration therapy on the basis of best available evidence.We developed a decision model for chronic hepatitis C virus infection representing two treatment strategies: 1) standard-duration therapy with pegylated interferon alfa and ribavirin for 48 weeks in patients with genotype 1 or 4 and for 24 weeks in patients with genotype 2 or 3 and 2) truncated therapy (i.e., 50% decrease in treatment duration) in patients with rapid virologic response. Patients for whom truncated therapy failed began standard-duration therapy guided by genotype. We used a Markov model to estimate lifetime costs and quality-adjusted life-years.In the base-case analysis, mean lifetime costs were $46,623 ? $2,483 with standard-duration therapy and $42,354 ? $2,489 with truncated therapy. Mean lifetime quality-adjusted life-years were similar between the groups (17.1 ? 0.7 with standard therapy; 17.2 ? 0.7 with truncated therapy). Across model simulations, the probability of truncated therapy being economically dominant (i.e., both cost saving and more effective) was 78.6%. The results were consistent when we stratified the data by genotype. In one-way sensitivity analyses, the results were sensitive only to changes in treatment efficacy.Truncated therapy based on rapid virologic response is likely to be cost saving for treatment-naive patients with chronic hepatitis C virus infection. Cost-effectiveness varied with small changes in relative treatment efficacy.",2012-01-09789,22999138,Value Health,Ziad F Gellad,2012,15 / 6,876-86,Yes,22999138,"Ziad F Gellad; Andrew J Muir; John G McHutchison; William Sievert; Ala I Sharara; Kimberly A Brown; Robert Flisiak; Ira M Jacobson; David Kershenobich; Michael P Manns; Kevin A Schulman; Shelby D Reed; Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response, Value Health, ; 15(6):1098-3015; 876-86",QALY,Not Stated,Not Stated,Not Stated,"Response-guided/truncated therapy: varied on basis of genotype, baseline viral load for genotype 1, and presence of rapid viorlogic response at week 4 vs. Standard duration arm: ribavirin and pegylated interferon alfa for 24 or 48 weeks",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-85380,United States,2010,-101337.65
